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Abstract
Phacoemulsification is a surgical technique in which a cataract is extracted and
replaced with an intraocular lens implant. This can be done under intravenous sedation,
oral sedation, or no sedation, in addition to local anesthetic techniques. The purpose of
this systematic review and meta-analysis is to assess the effectiveness of intravenous
sedation versus non-intravenous sedation methods. Results found that intravenous
sedation was significantly associated with a decrease in pain when compared to nonintravenous methods (SMD = -0.86, 95% CI 1.49 to -0.23, p=0.0008) (WMD = -1.01,
95% CI -1.66 to -0.36, p=0.002). The subgroup analysis found patients did not have a
statistically significant reduction in pain when using intravenous sedation over oral
sedation. The meta-analysis of perioperative complications found that intravenous
sedation did not have a statistically significant increase in adverse events when
compared to non-intravenous anesthesia techniques. These findings could inform policy
and help develop definitive guidelines for sedation and anesthesia strategies during
phacoemulsification.

Keywords
Cataract, cataract surgery, phacoemulsification, intravenous sedation, sublingual
sedation, pain, complications, ophthalmology, systematic review, meta-analysis
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CHAPTER 1

Introduction & Thesis Objectives

1.1. Financial Cost of Cataracts
The focus of this thesis will be to analyze sedation techniques during cataract
extraction surgery. I will first give an overview of cataracts, and their financial burden in
Canada.
According to the World Health Organization’s latest assessment in 2010,
cataracts account for 51% of global blindness, representing more than 20 million people
worldwide.1 Cataracts are a significant problem not only globally, but in Canada as well.
In Canada, cataracts are responsible for 16% of vision loss (Figure 1.1); the
direct and indirect financial cost of cataracts to the health care system is 1781.4 million
dollars.2 Further, the number of Canadians with vision loss is expected to double in the
next 25 years due to the aging population.2 Unless policy changes are implemented to
battle the rising costs of vision loss, the health care system will become even more
overburdened affecting the lives of many Canadians.
Figure 1.1: Prevalence of Vision Loss by Cause
Age-Related
Macular
Degeneration
11%
Cataract
16%
Refractive
Error/Other
66%

Diabetic
Reinopathy
4%
Glaucoma
3%

Recreated from: CNIB, Canadian Ophthalmology Society, Access Economics Pty Limited. The Cost of
Vision Loss in Canada: Summary Report; 2008.
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In general, vision loss places a large economic burden on the Canadian health
care system. The financial cost of vision loss in Canada was estimated to be $15.8
billion2 in 2007, which is consists of indirect health-related costs ($7.2 billion) and direct
costs ($8.6 billion) (Figure 1.2).2,3 The largest burden is placed on the federal and
provincial government at 55%.2 Additionally, vision loss is responsible for the highest
direct cost to the health care system compared to any other condition in Canada,
including all cancers, cardiovascular disease, mental disorders, respiratory disease, and
endocrine disorders such as diabetes (Figure 1.3).2 This is a result of Canada’s aging
population, specifically, the large group of baby boomers which have deteriorating vision
that require publicly funded care from optometrists, ophthalmologists, and opticians,
requiring specialized devices and equipment.2
Figure 1.2: Total Financial Costs of Vision Loss in 2007
10
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8
6

4.4

4
2
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0.305

0.7

Other Indirect
Costs

Care and
Rehabilitation

0
Transfer Costs

Lost Productivity

Cost (in billions)

Direct (Health
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Recreated from: CNIB, Canadian Ophthalmology Society, Access Economics Pty Limited. The Cost of
Vision Loss in Canada: Summary Report; 2008.

3

Figure 1.3: Direct Costs of Vision Loss Compared to Other Diseases
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Recreated from: CNIB, Canadian Ophthalmology Society, Access Economics Pty Limited. The Cost of
Vision Loss in Canada: Summary Report; 2008.

1.2. Cataracts & Treatment
A cataract is a clouding of the normally clear lens of the eye (Figure 1.4). It is so
highly prevalent because it is an inevitable consequence of aging. The lens is mainly
comprised of water and protein, arranged in a way that keeps the lens clear. However,
as we age the protein may begin to clump together forming the cataract. A cataract may
develop due to a number of reasons, which are further explained in Chapter 2. With
time, a cataract progresses, making it more difficult to see.4 An untreated cataract can
cause legal blindness in an individual. The Canadian Ophthalmology Society (COS) and
Canadian National Institute for the Blind (CNIB) claim that “every Canadian will develop
cataracts if they live long enough”.2 Surgical intervention is required for treatment as
there are no known conservative or medical options to alleviate cataract development.
During modern day cataract extraction surgery (known as phacoemulsification), the
clouded lens is removed, and replaced with a clear, artificial lens. This procedure can
be performed in approximately 15 minutes, is very safe, highly successful, and restores
vision to 95% of patients after surgery.5 However, there are over 2.5 million5 Canadians
with cataracts. This means a great deal of cataract surgery is required now, with a
projected increasing need in the coming years due to Canada’s aging population. In
2004, the government signed the 10-Year Plan to Strengthen Health Care, with the aim
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of reducing wait times in five priority areas.6 It speaks volumes that one of selected
areas is cataract surgery; it is a very common and important procedure that consumes a
substantial part of the health care budget. Maximization of visual potential is an
essential element in keeping Canadians independent, and contributes to a favorable
health related quality of life. A safe, effective, accessible, and cost conscious approach
would ensure optimal management of the current, and anticipated, need. It is for this
reason that the sedation and anesthesia techniques surrounding cataract extraction will
be discussed next.
Figure 1.4: Anatomy of the eye and location of Cataract7

Source from: https://aapos.org/terms/conditions/31

1.3. Perioperative Anesthesia Techniques Associated with Cataract
Surgery
Cataract surgery is performed under a wide range of anesthetic techniques,
sedation, and monitoring options. Anesthesia can occur as a combination of the
following: perioperative injections, intraocular injections, topical anesthesia, and
lidocaine gel. Additionally, conscious sedation may or may not be used in addition to
topical anesthesia and/or ocular injections. When conscious sedation is used, it can be
administered intravenously or sublingually.
There is little concrete knowledge regarding the trade-offs in complications
among commonly used techniques, or patient perceptions of pain and preference. The
majority of cataract surgeries in North America are performed using neuroleptic
anesthesia with the presence of an anesthesiologist or anesthetist to monitor vital signs
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and administer sedation intravenously, but at an international level there is significant
variation in the management of anesthesia strategies8.
A substantial cost in cataract surgery can result from the anesthesia and
sedation strategy. When intravenous neuroleptic sedation is included as part of the
anesthesia management strategy, it calls for the added personnel cost of anesthesia
nurses and anesthesiologists, as well as preoperative, intraoperative and postoperative
medications, and several disposable materials associated with the intravenous therapy.
Anesthesia assistants may also be used depending on the model employed. Cataract
surgery can also be performed without any sedation, or with sublingual sedation, both
methods eliminating the additional personal and materials needed for intravenous
sedation. An article by Schuster, Standl, Wagner et al.9 details the cost of anesthesia in
different subspecialties. It was found that anesthesiologists spend the least amount of
time with a single patient in ophthalmology, but that the cost of anesthesiologists are
highest in ophthalmology.9 A cost analysis study10 published in 2001 found that the
most cost effective anesthesia management in cataract extraction was oral sedation,
with an ocular block, and without an anesthesiologist available ($16.47). The most
expensive method involved intravenous sedation, topical anesthesia, and the presence
of an anesthesiologist present throughout the operation ($324.72). The question
becomes whether having intravenous (IV) sedation (and the extra cost that comes along
with it) is an advantage or disadvantage to the patient and their health outcomes? A
systematic review comparing the effects of intravenous sedation versus nonintravenous sedation methods has never been done before to answer this question.
This is the topic of my thesis.

1.4. Thesis Rationale
Currently, there are no systematic reviews and meta-analyses on the utilization
of intravenous sedation compared to non-intravenous methods (whether that is no
sedation, or oral/sublingual sedation) on our primary outcomes – patient pain and
complications during cataract extraction. The effects of pain perception and adverse
complications have not been quantitatively summarized to present a common effect.
Presently there are no standards or guidelines for the choice of sedation during

6

phacoemulsification, and the decision relies entirely on the preference of the
ophthalmologist, the anesthesiologist, or the administrators in the location where the
surgery is performed. It is very apparent that intravenous sedation is associated with an
amplified operating cost – costly personnel (such as anesthesiologists, anesthesia
assistants), medications, and equipment is mandatory in most clinics in North America
as soon as intravenous therapy is involved. In an article by Reeves et al10, intravenous
therapy costs 11 times as more, on average, when compared to oral sedation. That is a
tremendous difference.
As mentioned in the literature review, there is a split in the literature on which
method produces better sedation. There are studies11–13 that conclude sedation is not
needed for adequate pain control during cataract surgery, with topical/local anesthesia
being sufficient. On the contrary, other studies14–16 show that intravenous sedation
increases patient comfort and surgeon satisfaction, and decreases anxiety. Although
there are a small number of randomized controlled trials measuring pain during cataract
extraction, the results have not been summarized to produce an overall effect size. In
this study, we propose to address both of these gaps in the literature (IV sedation vs.
non-IV methods on perioperative pain and adverse complications), to be able to
meaningfully contribute to the body of knowledge surrounding anesthesia and sedation
during cataract surgery.

1.5. Thesis Objectives
The objective of this study is to synthesize the literature on non-intravenous
sedation methods versus intravenous sedation use via a systematic review and to
conduct a meta-analysis to generate effect measures when comparing the primary
outcomes of this study which are patient pain and perioperative complications. This
thesis has the potential to impact resource allocations in both publicly and privately
funded environments.

1.6. Structure of Thesis Document
This thesis is presented in monograph format in compliance with the standards
outlined by Western University School of Graduate and Postdoctoral studies. I
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conducted a systematic review and meta-analysis that met eligibility criteria. The
following list briefly describes the content found in each chapter:
•

Chapter 1 (introduction) describes a brief introduction to the topic,
alongside the objectives and rationale.

•

Chapter 2 (literature review) describes the terminology needed to
understand what cataracts are, the epidemiology of the disease, and the
history of surgical treatment.

•

Chapter 3 (literature review) describes the concepts and terminology that
is important for describing and interpreting the meta-analysis.

•

Chapter 4 (methods) describes the methods used to reach our objectives

•

Chapter 5 (results) summarizes the results for the systematic review,
quality assessment, meta-analysis, and publication bias analysis.

•

Chapter 6 (discussion) interprets and discusses the results, lists strengths
and weaknesses of the thesis, and possibilities for future research.
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CHAPTER 2

Literature Review

2.1. Introduction
The purpose of this thesis is to summarize the effects of intravenous sedation
use versus non-intravenous sedation methods in modern cataract surgery, when
comparing pain perception and the adverse complication rate. This chapter provides the
terminology needed to describe what constitutes a cataract and its associated
symptoms, etiology, and epidemiology. This chapter also goes into detail about the
surgical treatment (phacoemulsification), the anesthetic techniques, and possible
complications of cataract extraction. This is the first systematic review performed to
compare the effect of an IV method and a non-IV method of conscious sedation on
patient pain perception and complications during cataract extraction.

2.2. Classification of Cataracts
There are three main types of age-related cataracts: nuclear, cortical, and
posterior subcapsular (Figure 2.1).
Nuclear Cataracts - Nuclear cataracts are caused by the lens hardening and yellowing
over time. Also called “nuclear sclerosis”, these cataracts progress slowly over time,
and can eventually become a brown or black colour in advanced stages.17 They are the
most common type of cataract and the most common reason for cataract surgery to be
needed (Figure 2.1b).
Cortical Cataracts - In cortical cataracts, the cataract begins in the periphery of the
lens, moving towards the center, shaped like a spoke (Figure 2.1c). This occurs in the
lens cortex. Since this type of cataract starts in the outer edge of the lens, the bestcorrected vision may be unaffected for many years until the central portion of the lens is
affected. However, degradation of visual perception caused by glare and loss of
contract sensitivity may result.17
Posterior Subcapsular Cataract - This cataract type begins on the back surface of the
lens as a small opaque cluster. It forms adjacent to the lens capsule, hence the name
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“subcapsular”. The cataract will appear as small dust-like particles at first (Figure 2.1d),
eventually becoming thicker and more dense. Since light focuses through the back of
the lens, posterior subcapsular cataracts can cause excessive symptoms for their small
size including debilitating glare.17
Figure 2.1: Cataract Classification
(a) Normal Eye

(b) Nuclear Cataract

(c) Corticol Cataract

(d) Posterior Subcapsular Cataract

Source: Created by author

2.3. Symptoms of Cataracts
Symptoms of cataract include: blurred, clouded vision, a visual decline (distance,
near, or both) that can occur over weeks, months, or years, decreased color
discrimination, increased or extreme glare, halos or starbursts (Figure 2.2). Eventually,
corrective glasses are no longer being able to improve eyesight, or there may be double
vision in only one eye.18 Untreated cataracts can lead to an individual becoming legally
blind.
Figure 2.2: Glare, Halos, and Starbursts
(a) Source of light

(b) Glare

Source: Created by author

(c) Halo

(d) Starburst
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2.4. Etiology
There are a multitude of causes and risk factors that may contribute to an
individual developing a cataract. Cataracts may develop due to genetics, metabolism,
environmental factors, nutritional diet, local accidental or surgical trauma, local or
systemic medications, or from other systemic disorders such as diabetes.17
Age - Increasing age is the leading cause of cataract development. Oxidative damage
to the lens’ nucleic acids, lipids, and proteins is considered to be the dominant factor in
age-related cataract.17 As a result, the lens becomes cloudy and opaque.
Diabetes - Individuals with diabetes have a higher risk of developing cataracts. High
glucose levels in the lens are converted into sorbitol. When sorbitol collects in the lens,
it will cause it to become more opaque, eventually leading to cataract formation.19
Obesity - Obesity is yet another risk factor for cataract development. In fact, one study
found that a 2 unit increase in body mass index predicted a 12% increase in risk of
cataract in a proportional hazards model that adjusted for potential confounding
variables.20
Trauma - Blunt trauma to the eye can result in swelling and thickening of the fibers in
the lens, causing localized opacity.17 Additionally, previous eye surgery may cause
trauma to the lens, increasing the risk for cataracts.
Radiation / Excess Exposure to Sunlight - Ultraviolet light (particularly UVB) has
been shown to cause cortical and posterior subcapsular cataracts.21 The scientific
literature suggests that by wearing sunglasses, starting at a young age, it can provide
protection against developing cataracts.22
Genetics - A risk factor of cataracts that cannot be avoided is one’s genetics. The
cellular biology of the lens determines how prone an individual will be to developing
cataracts. This may be inherited, or secondary to another systemic disease.23 The
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current set of genes that are known to be associated with cataracts is extensive but far
from complete.
Smoking - Smoking is a known risk factor for numerous diseases. Tobacco smoke
contains hundreds of toxins and chemicals that play a role in development of cataracts.
A meta-analysis of the literature found that smoking was directly associated with an
increased risk of age-related cataract.24
Alcohol - Although there has been conflicting evidence over the relationship between
alcohol and cataracts, a well-designed population based prospective cohort study found
that daily consumption of 2 or more standard drinks was associated with an increased
likelihood of developing cataracts, thus requiring cataract surgery.25
Inadequate Vitamin C - A lack of vitamin C has been associated with an increased risk
of cataracts. It was found that increased vitamin C intake is associated with a reduced
risk of cataract.26
Corticosteroid Medication – Cataract development has been associated with the use
of inhaled corticosteroids. A systematic review conducted in 2009 found that the risk of
cataracts increased by approximately 25% per 1000µg daily dose of an inhaled
corticosteroid.27 This is a substantial risk for developing the most common cause of
blindness, due to cataract, internationally. Specifically, corticosteroid medication has
shown to be a significant factor for the development of posterior subcapsular
cataracts.28
Hypertension - A recent meta-analysis brought clarification to the indication that
hypertension may play a role in the development of cataracts. Yu et al (2014)29 found
that high blood pressure increases the risk of cataract anywhere between 8%-28%.
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2.5. Epidemiology
Globally
According to the World Health Organization, cataracts are the leading cause of
blindness, accounting for 51% of global blindness, representing more than 20 million
people worldwide.1 It also accounts for 33% of vision impairment worldwide.30 Although
cataract extraction is a highly successful and safe procedure (vision is restored to 95%5
of patients after surgery) there are immense barriers in many developing countries that
prevent individuals from having access to this crucial surgery, resulting in moderate to
severe disability.1 As a result, 90% of visually impaired people live in developing nations
without access to cataract extraction.31 With a large aging population globally, even
more people will be at risk for visual impairment due to cataracts in the coming
decades. It is tragic that 20 million1 people are blind due to cataracts when it is such a
treatable disease. Increased access to cataract surgery is vital to prevent disability and
increase quality of life for many individuals.
United States
In 2010, there were 24.41 million32 cases of cataracts, with 1.82 million33 cataract
extraction procedures performed in the United States. The following age specific
prevalence rates for cataracts in the United States display how common this condition
is; 24.75% of citizens aged 65-69, 36.49% of those aged 60-74, 49.49% of those aged
75-79, and a very significant 68.30% of those that are over 80 years old have
cataracts.32 Consequently, phacoemulsification (modern cataract surgery) is one of the
most commonly performed surgical procedures in any field. It has been estimated that
3.3 million33 surgeries will be performed in 2020, and that there will be 50.2 million32
individuals with cataracts in the United States by the year 2050. The increasing number
of cataract extraction procedures expected will place a growing strain on medical
resources and expenditures. Ensuring this procedure is cost effective is crucial to the
health care system.
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Canada
More than 2.5 million5 Canadians are currently battling cataracts in their everyday
life. In 2007, the direct health-related cost of vision loss in Canada was estimated to be
$8.6 billion, with indirect costs totaling $7.2 billion.2 55.3% of this burden comes directly
from Canada’s taxpayers via the federal and provincial governments, 22% from the
individuals with vision loss, 19% from society, and 4% from family, friends, and
employers (Figure 2.3).2 Cataracts are solely responsible for 16% of Canada’s vision
loss with a financial cost of 1781.4 million dollars.2
Figure 2.3: Financial Costs by Bearer, 2007
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Recreated from: CNIB, Canadian Ophthalmology Society, Access Economics Pty Limited. The Cost of
Vision Loss in Canada: Summary Report; 2008.

Like many other countries around the globe, the proportion those who are 65
years of age or older in Canada is rapidly growing. This is due to the “baby boomers”,
which were born after World War II, now reaching retirement age. In 1990, 11.3% of
Canada’s population was over the age of 65, this creeped up to 12.5% in the year 2000,
and 16.5% in 2016.34 The proportion of seniors will continue to increase in the coming
years; it is estimated that by the year 2036, seniors will represent between 23%-25% of
the population, and by 2061 they will represent between 24%-28%.35 Naturally, this
means that the need for, and number of, cataract surgeries in Canada will also
increase. In fact, the greatest demand for services in coming years among all surgical
specialties will be in ophthalmology.36 In 2012, Hatch et al.37 used Ontario’s population
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data to predict the volume of cataract surgery for the next 25 years. From the 143,000
cataract operations in Ontario in 2006, a 128% growth was projected, estimating
326,000 operations annually by 2036.37 It is feasible that this estimation can be applied
to a nation-wide level. Cataract surgery is, and will continue to be, one of the most
common surgeries in North America.

2.6. Treatment
When cataracts are diagnosed early, vision can be improved with new
prescription eye glasses, anti-glare sunglasses, magnifying lenses, or brighter lighting.
When cataracts begin to interfere with activities of daily living such as reading and
driving, and vision deteriorates, the only effective treatment is to remove the cataract via
surgical intervention.

2.7. A Brief History of Cataract Surgery
Couching
The oldest case of a cataract is documented in the form of a statue with a white
left eye from approximately 2460 B.C., located in Egypt. A wall painting from 1200 B.C.
depicts an oculist treating the eye of a workman. The tomb of a physician from 2630
B.C. filled with 30 bronze tools and writing on the walls suggests that ocular surgery,
specifically couching, was occurring.38 Couching is an ancient technique in which a
sharp tool is used to push the cloudy lens into the vitreous to settle at the bottom of the
eye. Once the patient begins to see movement or shapes, the procedure ends. Since
the patient no longer has a lens, a strong prescription eyeglass lens is required. In fact,
couching is still performed in remote, developing areas of the world.39 This technique is
extremely unsuccessful by today’s standards; a population-based survey located in rural
area of Mali in 1996 found that of those who had couching performed on their cataracts,
70.9% were left blind, and the remaining 29.1% had poor vision.40 Although this method
is often futile, it paved the way for the invention of new techniques.
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Intracapsular Cataract Extraction
In the 2nd century (year 100-200), a new technique was invented by the Greek
physician Antyllus, where the cloudy lens was removed with a hollow instrument by
suctioning. The entire lens including the capsule around it was removed. This method
ensured that the lens could not migrate back into the field of vision, unlike couching
which simply pushed the lens aside.41 This too, was an ineffective procedure by today’s
standards due to the amount of tissue disruption and complication rates. Nevertheless,
the intracapsular method was still the main method used until the early 1970’s. As the
20th century progressed, a cold icicle (a cryo probe) was used to extract the lens
relatively efficiently, and an artificial lens was placed in front of the iris which is not the
natural position of the lens. This was the only option as the procedure destroyed the
natural support structure, which is now retained in newer procedures that support the
lens implant.
Extracapsular Cataract Extraction
In 1747, a French ophthalmologist named Jaques Daviel was the first physician
to extract cataracts from the eye successfully. His method involved slicing a large
opening in the cornea and passing a small spatula through the pupil to extract the
lens.42 In this method, the capsule around the lens was kept intact and so the potential
to put a new plastic lens back in its proper position was born. Although an improvement,
this method had many potential complications at the time. Another surgeon named John
Taylor offered contributions around the same time to the procedure. He was known for
removing cataracts by breaking them into small pieces.38 As this technique was refined,
it became the main cataract procedure in the 1980’s and 1990’s. A large 6mm incision
was created in the eye and the front of the capsule peeled off. The lens was extracted
leaving the back of the capsule intact, and the new plastic lens put in this place, its
natural position.
The Intraocular Lens
On February 8th, 1950, Sir Nicholas Harold Lloyd Ridley invented the first
synthetic intraocular lens in London, England.38 Ophthalmologists worked to
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continuously improve this surgery, and in 1966 the first international conference on
intraocular lenses was held.
Modern Phacoemulsification
In 1967, Charles D. Kelman invented the start of modern phacoemulsification in
New York. Inspired by the ultrasonic probe his dentist used, Kelman recreated and
modified this concept so that ultrasonic waves can be used to liquefy the center of the
lens, allowing the cataract to be easily removed without a large incision.38 In principal
this surgery is the same as extracapsular cataract surgery except that the ultrasound
energy allows the lens to be vacuumed through a 2.5 mm incision. A foldable lens is
inserted through the same incision into the space in front of the retained capsular
support system. Kelman’s new technique resulted in a shorter hospital stay, quicker
healing and recovery, and decreased pain for the patient. Since its invention,
phacoemulsification has been improved and refined, becoming the gold standard
technique globally since the mid 1990’s.

2.8. Fundamentals of Modern Phacoemulsification
Phacoemulsification is the most common methodology employed for cataract
surgery today. During phacoemulsification, the surgeon first anesthetizes the eye with
topical drops, and possibly an ocular block for additional anesthesia. Additionally, the
patient may or may not be sedated via intravenous or sublingual methods. A small
incision that is approximately 3mm43 is then made on the cornea. An opening is
surgically constructed in the capsule that surrounds the cataract (a basement
membrane) and peeled anteriorly only. Next, an ultrasonic device with a very small
needle-like tip is used; this is called a phaco-probe. This device is inserted into the
incision, and its tip vibrates using ultrasonic frequency to emulsify the cataract, breaking
it into small pieces, which are then removed from the eye with suction.44 Once the
cataract has been completely removed, an intraocular lens (IOL) is implanted into the
space through the tiny incision into the remaining capsule. If the case is uncomplicated,
the IOL can be inserted into, and remain in, the normal anatomical position of the
human lens. The IOL is an artificial lens with various focusing powers, similar to
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prescription eyewear. The majority of patients will choose to have the focusing power of
their artificial lens prescribed so that they can see clearly in the distance, with reading
glasses for objects that are close. Technology in this area is rapidly advancing as
implants are now available that can potentially correct for corneal astigmatism and
presbyopia, causing patients to move even closer to complete spectacle independence
after surgery. After the IOL is implanted, the incision is usually able to heal on its own,
not requiring any stitches.45 Figure 2.4 summarizes the process. This procedure can be
performed, on average, in approximately 15 minutes, is done on an outpatient basis,
and recovery is nearly immediate. Since 1967 when this procedure was first introduced,
a multitude of improvements developed not only in the surgical technique, but in the
equipment as well. There were “better microscopes, phacoemulsification machines,
irrigation systems, sutureless incisions, and intraocular lenses all contributing to
increasing patient safety and [improved] visual acuity”.46 Consequently, the acceptance
of phacoemulsification rose from 16% in 198547 to 97% in 199648; the practice of
phacoemulsification became the universal technique in developed countries nearly 29
years after its invention.
Figure 2.4: Phacoemulsification

Source: http://concordeyecenternh.com/services-procedures/cataracts/#1447797946062-f9438d9ddc828088-6c82
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2.9. Introduction to Anesthesia and Sedation Strategies
Since the focus of this thesis is sedation and anesthesia techniques surrounding
cataract extraction, the focus will now turn to the available sedation and anesthesia
strategies. An extensive variety of anesthetic techniques are available for
phacoemulsification. These may include any of the following on their own or in
combination with each other: topical anesthesia with lidocaine gel, topical anesthesia
with anesthetic drops (i.e. proparacaine, tetracaine), periocular blocks, paraocular
blocks, intravenous sedation, and sublingual sedation. There is also a wide variety of
personnel and monitoring options available for the patient. Personnel required for
phacoemulsification to occur may include: surgical nurses, anesthesia nurses,
respiratory therapists, and anesthesiologists with or without assistants. Every model
exists in Canada, ranging from no monitoring, no pre-assessment and/or no
anesthesiologist present, to monitoring, pre-assessment, and/or an anesthesiologist
present. There is a wide range of anesthesia and sedation management available,
reinforcing the need for guidelines on the topic. This section will describe various
anesthesia techniques, sedation options, and the personnel involved.
In addition to local and/or topical anesthetic techniques, conscious sedation is
used to further complement anesthesia. The goal of conscious sedation is to allow the
patient to remain calm and cooperative, allowing the surgeon to perform the operation
without distractions. Sedatives, anxiolytics, hypnotics, and opiate analgesics are given
via oral, sublingual, or intravenous sedation. However, not using any conscious
sedation is also an option. Sedation is not mandatory or required, but may be a distinct
preference of many surgeons.

2.9.1. Conscious Sedation
The ability to be able to communicate with the sedated patient intraoperatively
with respect to eye placement has been shown to help the surgeon have greater
success.49 At the same time, patient movement caused by pain or anxiety can
negatively affect the surgery and potentially increase the complication rate. Thus, there
is a fine art to ensuring the patient is sedated enough so that they don’t feel pain, are
able to communicate, and at the same time are not overly sedated causing unintentional
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movement. It has been shown in various studies11–13 that sedation is not needed for
adequate pain control during cataract surgery, and that topical/local anesthesia is
sufficient. On the other hand, there are studies14–16 that show intravenous sedation
increases patient comfort and surgeon satisfaction, and decreases anxiety. There is a
split in the literature, showing the need for further research into the topic.
When the patient is sedated intravenously, the following is required: blood
pressure monitors, pulse oximetry, electrocardiogram monitors, supplementary oxygen
must be available, and trained resuscitation personnel and equipment must be standing
by.18 Presently, there are no national guidelines or standards for conscious sedation
during cataract surgery. The decision on which method to use is dependent on the
preference of the ophthalmologist, anesthesiologist, or the administrators in the center
where the surgery is performed. A range of practice patterns currently exist in which
patients can undergo cataract surgery with no conscious sedation at all, oral sedation,
sublingual sedation, or intravenous sedation. Intravenous sedation is associated with a
significantly higher cost, when compared to the other methods, and is one of the most
widely used techniques in North America. What is not known is whether intravenous
sedation is truly associated with better patient outcomes, less complications, and
significantly less pain? This is a particularly important question in view of the fact that
the cataract procedure itself has evolved significantly over the last few years, and
continues to evolve. Advancements have been made which require greater technical
skill, delivered in a shorter period of time. Moreover, there has been a trend for cataract
surgery to move out of hospitals and into privately-funded clinics. Historical methods of
perioperative anesthesia may not be the most optimal for the patients, the surgeons,
and the ambulatory settings in which the surgery is now being performed. The thesis
aims to address this question.
Intravenous Conscious Sedation
Intravenous conscious sedation may involve a combination of medications that
will help the patient relax (sedative) or block pain (anesthetic) without the loss of verbal
communication. The medicine is received through an intravenous line, is fast acting,
and allows for quick recovery. Common agents include: propofol, remifentanil,
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dexmedetomidine, midazolam, fentanyl, alfentanil, sufentanil or clonidine.50 Although
this method is common, like all anesthetic techniques, conscious intravenous sedation
is not without its risks. Respiratory depression, cardiac arrest (more pronounced in the
elderly and alcoholics), post-operative vomiting, increased intraocular pressure, reduced
blood pressure, pain during the injection of the intravenous line, patient movement,
increased intracranial pressure, hyper-salivation, muscle hyperactivity, constipation,
urinary retention, muscle rigidity, or airway obstruction are all potential risks and side
effects that may occur from intravenous sedation.51 In a prospective cohort study52 of
19,250 cataract surgery at nine centers in Canada and the United States of America
(USA), it was shown that the use of intravenous sedation was associated with a
significant increase in adverse effects and complications associated with topical and
injection anesthesia, compared to topical anesthesia without intravenous sedation. This
may have been a confounding situation where only the most anxious patients, or those
with more complicated procedures, were given intravenous sedatives. This may have
resulted in those with intravenous sedation having more complications.
Pharmacological knowledge is crucial when using sedative agents. For this
reason, the presence of anesthesia nurses or anesthesia assistants, as well as the
supervision of anesthesiologists are required in the United States53 and Canada54. If
there is a significant increase in complications, is intravenous sedation worth the extra
cost? It is difficult to answer this question using only one cohort study since there is less
power; for this reason we conducted a systematic review to compare the complication
rate when using intravenous sedation, compared to non-IV sedation methods.
Oral/Sublingual Sedation
Oral or sublingual sedation for cataract surgery is available as midazolam,
diazepam, or MKO (midazolam-ketamine-ondansetron) melt55 tablet. There are many
benefits to sublingual sedation; it is a more cost-effective sedation method, there is no
pain from the insertion of the IV line, and it eliminates many risks involved with
intravenous sedation. Additionally, an anesthesiologist is not required to be in direct
supervision during the surgery, but rather to be present in the center’s premises or on
call, which can result in great cost savings for the center and government. Chen et al.56
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found that when comparing oral diazepam to IV midazolam, the sublingual medication
performed better and was more cost effective. However, when choosing sublingual
conscious sedation, examining the patient is crucial; it may benefit those with extreme
anxiety to be given intravenous sedation.
No Sedation
Cataract surgery can also be performed with no conscious sedation. Local
anesthetics provide adequate anesthesia for the patient and surgeon to be satisfied with
the procedure. It is routine in many clinics to not sedate patients prior to cataract
extraction, but if anxiety occurs pre-operatively, a sublingual sedative can be given to
relax the patient.

2.9.2. Central Nervous System Medications via Intravenous Therapy
There are multiple functions of drugs that depress the central nervous system.
They can control seizures (anticonvulsants), relieve pain (narcotic analgesics), control
agitation (anxiolytic agents), and provide a calming effect (sedation).57
Benzodiazepines, barbiturates, and opiate analgesics are all classes of drugs
that may be used in phacoemulsification via intravenous therapy. Benzodiazepines are
a family of drugs that result in sedation, anxiolysis, relief of muscle tension, and
amnesia. Midazolam, diazepam, and lorazepam are all examples of drugs in the
benzodiazepine family.58 Barbiturates are central nervous system depressants that can
provide sedation and anesthesia (common barbiturates include thiopentone and
methohexitone). Opiate analgesics prevent the transmission of electrical nerve impulses
caused by painful stimuli. Examples of opiates include morphine and fentanyl.58
Anesthesia injection has been documented as one of the most painful aspects of
minor surgeries and procedures.59,60 There are many studies on the most effective way
to inject anesthesia in with the least amount of pain for the patient.61 For this reason, it
is important that those inserting intravenous lines are experienced and have excellent
technique. Another option is to avoid the use of intravenous injections when possible.
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2.9.3. Cost of Various Anesthesia Management Strategies
Chen et al.56 found that sublingual sedation was much more cost effective than
intravenous sedation; in their study, IV midazolam cost $2.50 per unit price, while oral
diazepam cost $0.03 per unit price. Similarly, in 2001 Reeves et al.10 conducted a
decision analysis to compare the trade-offs in costs, preferences, and benefits of
various anesthesia management strategies in cataract surgery. They found that the
most cost effective management was oral sedation with an ocular block, and without an
anesthesiologist available ($16.47), and that the most expensive method involved
intravenous sedation, topical anesthesia, with an anesthesiologist present throughout
the operation ($324.72). The study concluded that there are substantial cost savings
available for a small change in preference between sublingual and intravenous sedation
(Table 2.1). It is apparent that avoiding the use of intravenous sedation will result in
immense cost savings; in equipment, medication, and personnel. As previously
mentioned, one study52 found that the use of intravenous sedation was associated with
a significant increase in adverse effects and complications in comparison to surgeries in
which no sedation or oral sedation was used.
If intravenous sedation is more costly and causes more adverse events, should
we really be putting our limited healthcare dollars towards sedating patients
intravenously? Comparing complications during cataract extraction is one of the primary
objectives of this thesis. The other, is intraoperative pain perception. The result of these
two outcomes will determine the practicality of using intravenous sedation.
Table 2.1: Cost to Providers for Various Sedation Methods in Cataract Surgery
Sedation
Intravenous
Oral
Oral
Intravenous
Oral
Oral

Local Anesthesia
Block
Block
Block
Topical
Topical
Topical

Anesthesiologist
Present
On call
Not present
Present
On call
Not present

Cost
$324.42
$41.47
$16.47
$324.72
$41.77
$16.77

Recreated from: Reeves SW, Friedman DS, Fleisher LA, Lubomski LH, Schein OD, Bass EB. A decision
analysis of anesthesia management for cataract surgery. Am J Ophthalmol. 2001;132(4):528-536.

23

2.9.4. Topical and Regional Anesthetic Techniques
Retrobulbar Block
The first report of a retrobulbar block reported in 1884 by Herman Knapp in his
book “Cocaine and Its Use in Ophthalmic and General Surgery”, where he injected 4%
cocaine before ophthalmic surgery.62 With this method, a local anesthetic is injected into
the area behind the eye with a sharp needle (Figure 2.5), causing akinesia (loss of
movement) in the muscles surrounding the eye. The injection goes through the
extraocular muscle cone. Although this produces good anesthesia, some potential
complications include: retrobulbar hemorrhage, damage to the extra-ocular muscles,
ocular penetration, and diplopia.63 In 2003, a survey of the members of the American
Society of Cataract and Refractive Surgery (ASCRS)48 was conducted. It was found that
in 2003, retrobulbar blocks were used by 10% of the members, a large decrease from
1985 where 76% of members were using employing this technique.
Figure 2.5: Ocular Injections

Source: Created by author
Peribulbar Block
The peribulbar block was first introduced in 1986 by David Davis and Mark
Mandel as a safer alternative to retrobulbar block.64 With this method, a local anesthetic
is injected above and below where the eye of situated in the eye socket with a sharp

24

needle (Figure 2.6). This injection lies outside the extraocular muscle cone. Peribulbar
blocks produce excellent akinesia and anesthesia. Although safer than retrobulbar
blocks, complications are similar to those occurring with retrobulbar blocks, including
globe perforation.63 This use of this method has also decreased over the years with the
introduction of topical and Intracameral anesthesia. In 2003, 17% of ASCRS members
reporting using periocular blocks, down from 38% in 1995.48
Sub-Tenon’s Block
Sub-Tenon’s block (STB) is also known as parabulbar block, episcleral block,
and pinpoint anesthesia. This method was first described in 1884 by Turnball, in 1956
by Swan, and then re-introduced and popularized again in the early 1990s.65 SubTenon’s block involves inserting a local anesthetic with a flexible, blunt, cannula into the
sub-Tenon’s space (Figure 2.6). This newer method provides excellent anesthesia, and
reduces the risks typically associated with peribulbar and retrobulbar injections, mainly
penetrating globe injuries.17 A UK study found that the retrobulbar and peribulbar block
techniques had a 2.5-fold increased risk of complications compared with sub-Tenon’s
block.66 However, sub-Tenon’s is not without potential complications; globe penetration,
orbital hemorrhage, retinal ischemia, optic nerve damage, and orbital swelling are all
potential complications.67
Figure 2.6: Sub-Tenon’s Space

Source: Created by author
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Intracameral Injection
Intracameral lidocaine injections were first introduced in 1997 by Dr. James
68

Gills.

A local anesthetic is injected directly into the anterior chamber at the time of

surgery (Figure 2.7). Topical anesthesia is often complemented by Intracameral
injection of non-preserved lidocaine to ensure patient akinesia and anesthesia.
Intracameral injections are often complemented with topical anesthetic drops, as well as
a form of conscious sedation; this combination has largely replaced the use of
retrobulbar, peribulbar, and sub-Tenon blocks in North America.
Topical Anesthetic Drops
The use of topical anesthesia was re-introduced in 199249, later becoming the
standard of care for phacoemulsification. Topical drops are safe and efficient; they block
the conduction of nerve impulses, eliminating sensation. The following anesthetic
agents are used in ophthalmology: benoxinate, proparacaine, tetracaine, didocaine,
centbucridine, cocaine, phenacaine, dimethocaine, piperocaine, dibucaine, naepaine,
butacaine, xylocaine, oxybuprocaine, and proxymetacaine. Potential side effects to
these drops include: lens epithelial toxicity, stinging, decreased blinking, vasodilation,
corneal edema (swelling of the cornea), increased healing time, and allergic reactions in
a small percentage of patients. Additionally, they may cause incomplete anesthesia,
requiring multiple drops throughout the surgery. Agents used in phacoemulsification
today are tetracaine, proparacaine, and benoxinate, which last for 15 to 20 minutes.69
The most commonly used agent is lidocaine in gel form. The gel allows for a longer
lasting effect than liquid lidocaine preparations, and will be discussed in more detail to
follow.
Gel Anesthetics
Topical anesthetics are also available in the form of gel for ophthalmology. Gels
are advantageous in areas such as the eye, where it is surrounded by tear film which
may dilute topical anesthetic drops to reduce the effectiveness. A recent review70 on
lidocaine gel in ophthalmic surgery found that lidocaine gel is often more effective than
anesthetic drops for preventing pain related to cataract extraction, with few adverse side
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effects. Patient and surgeon satisfaction is generally high with this method, and is often
used in combination with topical anesthetic drops. Anesthetic gels also became very
popular as a cost-saving strategy by reducing the amount of nursing time involved in
preparing the patient for surgery. It is for all of these reasons that this is the most
commonly used anesthesia technique used today in modern phacoemulsification.
Mydriatic Drops (Pupil Dilation)
Mydriatics are a type of pharmaceutical drug that cause the pupil to dilate. In
phacoemulsification, this is achieved by the topical administration of mydriatic drops, or
intracameral injection. Mydriasis in cataract surgery is necessary for a successful
outcome.71

2.9.5. General Anesthesia
Although general anesthesia was used for the first time in surgery in 1846 by
dentist William Morton,72 it wasn’t until 1954 that general anesthesia was used for
cataract extraction.73 Today, general anesthesia is rarely used in cataract surgery due
to the associated higher risks74, and costs. Furthermore, non-general anesthesia
techniques are very effective. Nevertheless, general anesthesia today is used for
children, and uncooperative or disabled patients.63

2.10. Ocular Complications from Cataract Surgery
Although cataract surgery is a safe and successful procedure (vision is restored
to 95%5 of patients after surgery) there are always risks with any surgery, and
complications may result during or after the procedure. The complications may range
from minor inflammation to severe infection resulting in complete enucleation of the eye.
Surgeons, anesthetists, and nurses have many protocols and procedures put in place to
avoid and prevent complications throughout cataract surgery, from pre-op to post-op. As
previously mentioned, intravenous sedation has been associated with a higher rate of
complications in a large cohort study.52 If this is truly the case, sedation management
should be switched in order to reduce the following perioperative complications.75
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Posterior Capsule Rupture: A posterior capsule rupture is a tear in the posterior
capsule. This can result in vitreous from the posterior chamber flowing into the anterior
chamber of the eye.76 This is a complication that can happen at the time of surgery, and
is one of the most detrimental complications that can occur. A posterior capsule rupture
can lead to severe visual disability, and result in blindness from retinal detachment.
Furthermore, since the intraocular lens implant is ideally placed in the remaining
capsule, when the capsule is ruptured, proper placement of the IOL becomes very
challenging and sometimes impossible.
Retinal detachment: Retinal detachment is one of the most severe complications post
cataract surgery.77 The incidence of retinal detachment after phacoemulsification has
been reported to be 0.27% within one year of the surgery, and 0.71% within five years
of the surgery date.78 This condition occurs when the retina (thin layer of tissue at the
back of the eye) pulls away from the underlying retina pigment epithelium and choroid
which has blood vessels that provide it with oxygen (Figure 2.7).79 This can result in
permanent vision loss if not treated right away.
Figure 2.7: Retinal Detachment

Source: Mayo Clinic Staff. Retinal Detachment. Mayo Clinic. http://www.mayoclinic.org/diseasesconditions/retinal-detachment/home/ovc-20197289. Published 2016.
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Endophthalmitis: Endophthalmitis is rare (incidence: 0.023%80) but has potential to be
a highly destructive post-operative complication (Figure 2.8). Endophthalmitis is a fungal
or bacterial infection that may result in complete enucleation of the eye, and can occur
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up to 6 weeks after cataract extraction, but usually occurs in the first 10 days. It can also
be a chronic condition that reoccurs months and years after surgery.18 Infection usually
originates from the bacterial flora in the conjunctiva or lids. Less commonly involved
mechanisms can be: immunocompromised host, improper draping during the
procedure, contaminated instruments, rubbing the eye, and leakage from the site of
operation. 81 It is most often treated with intraocular injections of antibiotics or
antifungals, with subsequent surgery for more serious cases.75
Figure 2.8: Endophthalmitis

Source: Henderson BA, Pineda R, Chen SH. Essentials of Cataract Surgery. Second. Slack Incorporated;
2014.
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Suprachoroidal hemorrhage (SCH): This can occur during phacoemulsification or in
the immediate postoperative period. A SCH is, in most cases, an explosive
accumulation of blood in the suprachoroidal space due to low intraocular pressure in the
eye during surgery.82 This is a devastating complication as it can result in severe vision
disability, total loss of vision, or even phthisis, which is a shrunken, non-functioning eye.
Fortunately, the small incisions of modern phacoemulsification make this complication
very rare.
Corneal edema: Corneal edema is swelling of the cornea, and one of the most
common complications post-cataract extraction. This can result from increased
intraocular pressure, inflammation, trauma from the operation, or chemical injury.75
Although the procedures and instruments used for cataract extraction have improved a
great deal over the past decade, there is still the possibility that the cornea may be
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injured which may result in the patient developing a corneal edema. Persistent corneal
edema can result in the need for corneal transplantation.
Descemet membrane tear and detachment: This is an iatrogenic injury to the cornea
that results in corneal edema, and can be a very serious complication after cataract
extraction. This occurs when Descemet’s membrane is torn out during routine
phacoemulsification. Descemet’s membrane is the membrane that lies between the
stroma and the endothelial layer of the cornea. This can affect visual acuity, however
with medical treatment and time, reattachment is possible.75
Intraocular lens dislocation: This complication can occur immediately after or many
years after phacoemulsification. As mentioned in the posterior capsule opacification
description, the IOL is placed inside the capsular bag of the original lens. However, this
capsular bag is fragile and thin – approximately as thick as a single red blood cell! It can
rupture, break, dislocate, or dislodge and move positions. This can result in decreased
visual acuity or double vision. If treated in a timely manner, the IOL can be repositioned
successfully in a second procedure. In more severe cases, an entirely new IOL may
need to be implanted into the eye.83
Posterior capsule opacification (PCO): This is the most common postphacoemulsification complication. It is sometimes referred to as a “secondary cataract”
even though it is not a cataract at all. During cataract surgery, although the lens is
removed and replaced with an intraocular lens, the outer clear membrane (lens capsule)
that surrounds the lens is left intact. However, between 11.8%-28.4%84 of patients
develop haziness due to epithelial cells growing on the lens capsule. This can cause
decreased visual acuity, and in some cases, be worse than before the cataract
extraction.84 Fortunately, there is a laser surgery (Nd:YAG laser capsulotomy) able to
correct this problem efficiently and painlessly.
Cystoid macular edema (CME): CME is a condition that affects the central retina or
macular, in which multiple cystic spaces appear in the macular and cause retinal
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swelling or an edema (excess of fluid collecting).85 This typically takes 6-8 weeks to
appear after the procedure, and is the most common cause of decreased vision clarity.
The incidence of CME after cataract surgery was found to be between 1%-2%.18,75,86
Although most cases of CME can resolve on their own, topical non-steroidal antiinflammatory drugs are often applied.87 The next step in treatment is topical steroids.
Surgically induced astigmatism: Astigmatism can result from poorly constructed
surgical wounds, overly tight sutures, or thermal injury during phacoemulsification.75
Astigmatism is a refractive error which causes images to be blurred or distorted.
Although this can be corrected with eyeglasses, contacts, or refractive surgery such as
laser eye surgery, avoiding this complication is always better for the patient.
Dysphotopsias: This is a common side effect after uncomplicated cataract surgery.
Dysphotopsias are unwanted visual manifestations occurring from light that is reflected
off the IOL and onto the retina. Positive dysphotopsias results in glare, streaks of light,
haloes etc. Negative dysphotopsias occurs as a dark crescent in the visual field.75
Toxic anterior segment syndrome (TASS): TASS is a noninfectious inflammation of
the anterior segment of the eye that materializes within 24 hours of cataract extraction.
Symptoms typically include corneal edema and clumps of white cells in the anterior
segment of the eye.88 If not treated immediately, vision loss can occur.
Post-operative inflammation: All intraocular procedures will result in some degree of
inflammation, which is a risk factor for more serious complications. If inflammation
worsens, decreased vision can result. Steroids drops and anti-inflammatory drops are
generally prescribed to the patient to prevent such scenarios.75

2.11. Systemic Complications during Cataract Surgery
Pain: Pain is a common complication of surgery – especially when the patient is awake
and conscious for the procedure. Although surgeons and nurses go to great lengths to
ensure cataract extraction be as pain free as possible, pain still occurs in patients.
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Additionally, inserting an intravenous line can cause a patient great pain, especially if
they are an older adult with frail veins who gets “poked” several times by a nurse trying
to locate the vein.
Hypertension: High blood pressure is one of the most common medical conditions
globally.89 Cataract extraction surgery is one of the most common surgeries today, and
generally affects adults over 60, the exact group plagued the most from hypertension.
Anxiety about undergoing a surgical procedure may exacerbate a patient’s
hypertension, requiring the surgery to be postponed or rescheduled.
Unwanted movement: Unwanted eye and head movement is a potential complication
resulting from the anesthesia management strategy used intra-operatively. The ocular
or systemic anesthesia may cause the patient’s eye to move, making the procedure
more challenging for the surgeon. Systemic sedation may cause the patient’s head to
move as well, which is why most clinics reinforce the patient’s head to a stationary
position. Movement may cause the surgical instrumentation to unintentionally move,
which can cause immense complications with such a microscopic procedure.
Post-Operative Nausea and Vomiting (PONV): PONV occurs in 20-30% of patients in
the first 24 hours after surgery.90 This can occur from intravenous therapy, sublingual
sedation, or inhalation anesthesia.

Bradycardia: Bradycardia is an abnormally slow heart beat; less than 60 beats per
minute in adult to be exact.91
Tachycardia: Tachycardia is an abnormally fast heart beat; more than 100 beats per
minutes in adults.92
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CHAPTER 3

Literature Review for Methodology

3.1. Introduction to Meta-Analysis
The Cochrane Collaboration has been a meticulous leader in the development of
the methods surrounding systematic review and meta-analyses. For this reason, much
of this chapter will be referring to their guidelines and tools. According to the Cochrane
Handbook, a meta-analysis is the “statistical combination of results from two or more
separate studies”. This is often the next step after a systematic review, synthesizing the
results of the included studies.
Meta-analyses most commonly concentrate on pair-wise comparisons of
interventions. In a meta-analysis of randomized control trials, this comparison is
between the experimental intervention versus the control, or a comparison between two
experimental interventions. In terms of this thesis document, we will conduct a metaanalysis to statistically analyze the studies included in the systematic review, which
compare intravenous sedation versus non-intravenous methods in phacoemulsification.

3.2. History of Meta-Analysis
The first documentation of a meta-analytic concept can be traced to the 17th
century, where astronomers combined an independent set of observations.93 Then, in
1904, statistician Karl Pearson published an article combining the results of multiple
clinical studies on typhoid vaccination; this was another meta-analytic approach.94 In
1940, the first genuine meta-analysis was published by psychologists from Duke
University.95 However, meta-analyses of medical interventions were not regularly done
until the 1970’s.96 Up until 1976, this form of statistical analysis was known as an
advanced form of secondary analysis. Then, in 1976, modern statistician Gene Glass
invented the term “meta-analysis” in a published article.97 Today, meta-analyses are
common, and are considered the strongest type of study in the hierarchy of evidence
(Figure 3.1).

33

Figure 3.1: Hierarchy of Evidence

Source: Created by author

3.3. Reasons to Conduct a Meta-Analysis
According to the Cochrane Handbook98 there are four major reasons to conduct
a meta-analysis when conducting a systematic review. These are: to increase power,
improve precision, compare studies, and settle controversies. These will be further
explained below.
Power
Power is “the chance of detecting a real effect as statistically significant if it
exists” (The Cochrane Collaboration, 2008). In other words, the likelihood that an effect
will be detected, when there truly is an effect to be detected. Statistical power is affected
by two main study characteristics: The size of the effect (a larger effect is easier to
detect than a smaller effect), and the sample size (larger samples will have a greater
proportion of positive results). Power calculations are done to determine what the
minimum required sample size is to detect a specific effect size. Generally, researchers
and scientists aim for a statistical power of at least 0.8; in other words, there will be an
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80% chance of detecting a real effect if the calculated sample size is enrolled with
complete data (including variables, participants, results, follow-up etc).
A meta-analysis should be included in reviews because the power of the
combined studies increases. Many studies have too small of a sample size to detect an
effect, but when multiple studies are combined, there is a greater chance of detecting
an effect. For example, a small study may have a 50% chance of detecting an effect,
whereas a large study, or combined studies from a systematic review and metaanalysis, may have a 90% chance of detecting an effect.
Precision
Accuracy and precision are often used interchangeably, however, the distinction
between the two is crucial in scientific research and literature. Accuracy involves how
close you get to the correct result i.e. If you obtain a weight of 2kg for an item, but the
item truly weighs 10kg, it is not accurate. Precision is how consistently you get a result
using the same methods. If you weigh the item 10 times, and each time it weighs 2kg,
then the measurement is very precise, but inaccurate. If the items weigh 10kg each
time, then the measurement is precise and accurate. If the items have a different weight
each time, then the measurement is neither precise nor accurate. Precision and
accuracy are independent of each other.
Precision is a key reason to conduct meta-analyses in systematic reviews.
Testing for precision will allow us to determine how consistent the effect size is over
multiple studies. The estimation of an intervention effect will be improved when it is
based on multiple studies testing the same outcome.
Consistency
Randomized controlled trials typically involve a specific type of patient, with prespecified, definite interventions. A group of studies with slight variations in the
population and intervention will allow researchers to study how consistent the effect is.
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Settle Controversies
There are many instances where multiple studies studying the same exact
intervention have opposite, conflicting, results. Analyzing all the results together to
produce a summary effect allows researchers to determine where the true effect lies,
producing a more accurate result.

3.4. True Effect Size, Observed Effect Size, and Summary Effect Size
The true effect size is what the correct answer to a research question would be
for the underlying population of a study, if the entire population was used as the study
sample, and not a small, random, percentage of the population. The observed effect
size is the effect size that is measured from the small, random sample of the population
in a research study. The summary effect size is the result when a meta-analysis is
performed. This measure is the weighted mean of the observed effect sizes of all the
included studies. There are two models for calculating the summary effect size, which is
described in the next section. One is the fixed effects model, and the other is the
random effects model.

3.5. Random Effects versus Fixed Effects
When conducting a meta-analysis, there are two models for calculating the
summary effect size using a software package; fixed effects models and random effects
models.
Fixed-Effects
When a meta-analysis is conducted with fixed effects modeling, it is assumed
that the true effect is the same in each study, and that the different effect sizes between
studies is solely due to chance.99 In this scenario, if all the studies are conducted in the
same exact way, then the true effect size would theoretically be the same in every
study. The difference between the true effect size and the observed effect size is the
error, thus, if there are variations in the observed effect size, it is due to intrinsic random
error in each study, such as sampling error or measurement error. To use fixed effects
models, two conditions must be met. First, the researchers must conclude that all the
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studies in the analysis are identical in terms of the underlying population, intervention,
comparator, outcome, study design, and the methods. Second, the goal is to determine
the effect size for the identified population, and not to generalize to other populations.100
An example of a meta-analysis using fixed effects models would be if a pharmaceutical
company wanted to run a trial using 500 patients, but only had enough resources to test
100 patients at a time. They would then run 5 trials, using 100 patients each time, and
use fixed-effect models.100 Since there is less heterogeneity in fixed effects models, the
treatment effect will be more precise, producing smaller confidence intervals.
Random-Effects
When a meta-analysis is conducted with random effects modeling, it is assumed
that the true effect in each study will vary around an overall average treatment effect.99
In this scenario, if all the studies are conducted in the exact same way, the true effect
size in each study would be close, but not identical. There is random error within each
study, and between the studies. In random-effects modeling, the aim is to estimate the
mean of the distribution of effects.100 To use a random-effects model, two conditions
must be met. First, the included studies have been performed by researchers working
independently and/or at different institutions. Second, the goal of the analysis is to
generalize to multiple populations. An example of a random-effects model would be a
meta-analysis of 10 randomized controlled trials that were independently conducted in
different countries, with non-identical populations. Since there is more heterogeneity in
random-effect models, the treatment effect will be more conservative, resulting in wider
confidence intervals.

3.6. Heterogeneity
Heterogeneity can be described as any kind of variability between individual
study results in a systematic review.98 Heterogeneity is difference between studies that
are not due to chance. There are three main types of heterogeneity.
Clinical heterogeneity: This occurs when there is variability in the characteristics
of participants, interventions, and outcomes (how they are defined and measured).
Clinical heterogeneity is always present, as the patients in each study will always be

37

different. Even if two studies are giving patients the exact same drug, it can be given in
different quantities, introducing heterogeneity from the intervention. It is important to be
rigorous in the inclusion and exclusion criteria when screening articles to reduce
variability as much as possible in the PICOS.
Methodological heterogeneity: This occurs when there is variability in study
design and degrees of bias (blinding, concealment allocation). Another manner to
introduce methodological heterogeneity is each study having a different scale to
measure the outcome. For example, one of the primary outcomes this thesis is
investigating is the pain levels during phacoemulsification. Each study will certainly be
using different pain scales to measure this, which will introduce heterogeneity into the
analysis.
Statistical heterogeneity: This occurs when there is variability in intervention
effect sizes, and is due to clinical and/or methodological heterogeneity. In other words,
studies that have different results from each other. For example, one study may show
that a pharmaceutical intervention is harmful, while the other shows it is beneficial.
When there is statistical heterogeneity, the true effect is different in each study.
It is crucial that meta-analyses are generated only when the PICOS (population,
intervention, comparator, outcome, and study design) across studies is reasonably
homogenous.

3.7. How to Measure Heterogeneity (I2)
Heterogeneity is a descriptive statistic (also known as I2) that can only be
evaluated when a forest plot is created during a meta-analysis. Heterogeneity is always
present to some degree in a systematic review. A way to measure if heterogeneity is
present is to examine the p-value of a chi-squared (χ2, or Chi2) test, which tells us if it is
fair to combine the studies in the meta-analysis, or if they are too different. A chisquared test assesses how likely it is that the observed distribution of results is due to
chance; it measures how well the observed distribution fits with the expected
distribution.98 Expressed differently, the chi-square test tests the null hypothesis that all
studies are evaluating the same effect, and that they are homogenous. A high p-value
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(over 0.5) suggests that homogeneity is present. A low p-value suggests there is
heterogeneity present, and that the variation of effect estimates is beyond chance.98
The I2 is the perception of variation across studies that is due to heterogeneity,
and not due to chance. According to the Cochrane Handbook, 0%-40% represents low
heterogeneity, 30%-60% represents moderate heterogeneity, 50%-90% represents
substantial heterogeneity, and 75%-100% represents considerable heterogeneity.98 An
issue with the chi-squared test is that it has low power (the likelihood that an effect will
be detected, when there truly is an effect to be detected, is low). This is because there
are usually very few studies included in a meta-analysis. Once heterogeneity is
identified, there are two ways to investigate where it may be coming from: subgroup
analysis, and meta-regression.

3.8. Investigation of Heterogeneity
Subgroup Analysis
A subgroup analysis involves separating all the data into subgroups to make
comparisons between them. This may be impactful to conduct, as some patients may
have more benefit, more harm, or neither benefit nor harm. Clinically, it is important for
a physician to know if there is a certain patient group that would benefit from an
intervention, while another patient subgroup may be harmed by the same therapy.
These analyses can be done either by comparing subsets of participant characteristics
(i.e. opposite sex, age, ethnic groups, presence of disease), treatment characteristics
(i.e. high dose vs. low dose, intravenous vs. non-intravenous, intravenous vs. oral, etc.),
or study characteristics (i.e. by location).
Meta-Regression
A regression analysis is a statistical method to estimate relationships among one
or more explanatory variables. The relationship between a dependent and independent
variable is quantified with a line of best fit, allowing researchers to predict the outcome
variable (Figure 3.2).
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Figure 3.2: Regression Analysis Example

Source: Created by author on STATA13

A meta-regression uses the same concept of a simple regression but in the
context of a meta-analysis, with the aim being to predict the outcome variable of a metaanalysis. In a meta-regression, the outcome variable is the effect estimate (i.e.
standardized mean difference, mean difference, risk ratio, odds ratio, risk difference,
etc), with the explanatory variables being characteristics of studies (i.e. study location,
year of study, type of study, male/female, mean age of participants, etc.) with potential
to influence the intervention effect size. The regression coefficient from a metaregression describes how the outcome variable changes with a unit increase in the
explanatory variable.

3.9. Statistical Principles of Meta-Analysis
A meta-analysis is done in two stages. First, a summary statistic is calculated for
each individual study. If the data are continuous (quantitative traits measured on interval
scales such as height, weight, blood pressure etc.) the summary statistics will be a
difference between the means. If the data are dichotomous (can only take on the value
0 or 1 i.e. if the individual has clinical improvement it is 1, if the individual does not it is
0), the summary statistic may be a risk ratio or an odds ratio.101
The second stage of a meta-analysis is the calculation of a summary intervention
effect. A weighted average of all the intervention effects (which are calculated in the first
stage) are pooled. If a random effects meta-analysis is performed, it is assumed that not
all included studies are evaluating the same intervention effect, but that a distribution
across studies is followed. If a fixed-effect meta-analysis is performed, it is assumed all
included studies are evaluating the same exact intervention effect.
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These two stages are visually displayed on a forest plot (Figure 3.3); the effect
estimates and confidence intervals for both the individual studies and overall summary
effect are presented. The individual studies are represented by a square at the effect
estimate, with the size of the block depicting the weight of the study. The horizontal line
passing through the block is the confidence interval.
Figure 3.3: Forest Plot Example

Source: Created by author in RevMan.

3.10. Effect Measures for Dichotomous Outcomes
In clinical trials with dichotomous data, the most common effect measures are
the risk ratio (RR), odds ratio (OR), risk difference (RD), and number needed to treat
(NNT). The meta-analysis summary effect will describe the outcome in one group
relative to the other group. The risk ratio describes the probability of an event occurring
in the intervention group, to the probability of the event occurring in the comparison
group. The odds ratio describes the odds that an outcome will occur compared to the
odds of the outcome not occurring, in the presence or absence of an exposure,
respectively. A risk ratio or odds ratio of 1 indicates that the effects are the same in both
the intervention and comparator group. There are four well-established methods of
conducting a meta-analysis for dichotomous outcomes.
Inverse Variance Method (fixed effects)
This approach is used in both dichotomous and continuous data. The weight of
each study is analyzed as the inverse of the variance of the effect estimate
(1 ⁄ √(𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟)). As a result, larger studies (with smaller standard errors) are given
more weight than smaller studies (which have larger standard errors). The smaller the
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standard error, the more precise the study, therefore this method attempts to minimize
imprecision.98
DerSimonian and Laird Method (random effects)
This approach produces a random-effects, inverse-variance meta-analysis. It is
conducted on the assumption that the studies are estimating different intervention
effects that are related. In this analysis, the calculations are adjusted to account for
heterogeneity among the intervention effects.98
Mantel-Haenszel Method (fixed effects)
This approach is more appropriate than the inverse variance method when there
are rare events or very small trials. Instead of using the inverse variance of the effect
estimate to assign weighting to the studies, a distinct weighting scheme is used
depending on the effect measure (OR, RR, RD).98
Peto Odds Ratio Method (fixed effects)
This approach is an alternative method to the Mantel-Haenszel method for
pooling odds ratios when the events are rare. Corrections for zero cell counts do not
need to be done when using this method, as the focus of the Peto analysis is on rare
events.98

3.11. Effect Measures for Continuous Outcomes
In clinical trials with continuous data, the most common summary statistics are
mean differences, and standardized mean differences. The mean difference summary
statistic measures the absolute difference between the mean values in the intervention
and comparator groups in a clinical trial. This is used when each RCT in the analysis
uses the same outcome scale. The standardized mean difference summary statistics is
used when every RCT in the analysis measures the outcome in different ways i.e. each
study measures pain using a slightly different visual pain scale. This method
standardizes the results; the size of the each intervention effect is relative to the
standard deviation in that study.98 The scales may be different sizes, however they must
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all point in the same direction. Corrections can be made for scales in opposite
directions.
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝑒𝑎𝑛 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =

𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑚𝑒𝑎𝑛 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑔𝑟𝑜𝑢𝑝𝑠
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑎𝑚𝑜𝑛𝑔 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠

To perform a meta-analysis of continuous data using mean differences or
standardized mean differences, authors must extract the following from each study: the
mean value of the outcome measure in each group, the standard deviation of the
outcome value in each group, and the number of participants in each group
Inverse Variance Method (fixed effects and random effects)
There are two common methods of analysis for continuous outcomes: inverse
variance fixed effect method, and inverse variance random-effects method. When
heterogeneity is not present, both methods will give an identical answer. When
heterogeneity is present, confidence intervals for the effect sizes and summary effect
will be wider with utilization of the random effects method, and the P-values will be less
significant.

3.12. Effect Measures for Count Data
Count data in statistics is when the observations in an analysis only include nonnegative integer values. An example of using count data is to analyze the number of
complications occur in each treatment group in a study, or number of myocardial
infractions, hospital visits, etc. Count data may be analyze using dichotomous or
continuous methods. The most common summary statistic in a meta-analysis for count
data is the risk ratio.98 The mean difference of events will be used compare the
intervention group to the comparison group. In the case of zero event cells, a correction
of 0.5 may be added to the cell.
Count Data as Dichotomous Outcome
For count data to be treated as a dichotomous outcome, the number of
participants in each intervention group, and the number of participants in each group
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who experience at least one event must be extracted from each study. For this thesis,
we will be extracting complication outcomes as dichotomous count data.

3.13. Publication Bias – Funnel Plots
Publication bias is the tendency to submit or accept studies for publication based
on the direction or strength of the study result. This means that positive studies tend to
get published more than negative studies. The studies that are negative, or not as
strong as the researchers would like, never get submitted for publication. The reason
systematic reviews are done is to understand the totality of evidence on a given topic. If
publication bias exists, and non-significant studies are suppressed, we will not be able
to see all the evidence, and our systematic reviews and meta-analyses will yield a
biased estimate of an intervention effect. Negative studies not being published leads to
an overestimation of benefit and an underestimation of harm.
A commonly used visual method to assess publication bias is the funnel plot. A
funnel plot is a scatter plot of effect size (x-axis) against some measure of study size or
precision (y-axis). Each of the dots represents a study that was found by the
researchers. If the funnel is symmetric then there is likely not significant publication
bias. If the funnel is asymmetric, it suggests that there is possible publication bias. It is
much more likely for small negative studies to not get published, and a funnel plot can
visually display this. Figure 3.4 is an example of a symmetrical funnel plot, and Figure
3.5 is an example of an asymmetrical funnel plot which displays publication bias.
According to Egger et al. (1997)102 there are five possible sources of asymmetry
in funnel plots. The first is selection bias, which can include publication bias, language
bias, location bias etc. The second is true heterogeneity, meaning that the included
studies may not all be estimating the same effect or same intervention. This may lead to
heterogeneous results, causing asymmetry in the funnel plot. A third possible reason for
asymmetry is data irregularities. This can result from methodological quality differences
in the included studies; it is known that smaller studies tend to be conducted not as
meticulously as larger studies, and that lower quality trials are prone to showing larger
effect sizes.103–105 The fourth source of asymmetry may be due to artefactual bias.
Artefactual bias may occur because of the statistic chosen to measure the effect size.
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For example, if the event rate in a study is high and an odds ratio is calculated, the
relative reduction in risk may be overestimated.105 Lastly, an asymmetrical funnel plot
may be purely due to chance.102 It is important to take these possibilities into account
when examining a funnel plot.
Figure 3.4: Symmetrical Funnel Plot

Source: Created by author.

Figure 3.5: Asymmetrical Funnel Plot

Source: Created by author.
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3.14. Missing Data
A common issue when extracting data from a study is missing data. There are
five types of missing data: missing studies (publication bias), missing outcomes
(selective reporting bias), missing summary data (selective reporting bias), missing
individuals (selecting reporting bias), and missing study-level characteristics (incomplete
reporting).98 There are many options to manage missing data. The Cochrane Handbook
has dedicated an entire section to dealing with a common setback in meta-analyses
which is missing standard deviations from the included studies. If the corresponding
author from the study in question is not able to release the data from the paper, or no
longer has access to it, there are a multitude of ways to calculate the standard deviation
using available data in the study. This is known as imputation, and involves making
assumptions about the missing data and statistics.98 In instances where data was
missing from the included studies, we consulted the Cochrane Handbook on their
statistical methods to impute the data and an experienced researcher (WGH).

3.15. Risk of Bias Assessment
The Cochrane Collaboration is an international non-profit organization involving a
global group of researchers, professionals, patients, and individuals interested in health
and healthcare. It is a group of more than 37,000 individuals from 130 countries,
working to produce credible and accessible evidence-based reports and information that
is free from sponsorships and conflicts of interest.106 This group has published over
7000 systematic reviews and reports, a 674-page handbook containing all the
methodological guidance needed to conduct a systematic review of interventions, a data
management program (Review Manager 5.3, also known as RevMan) that enables
researchers to produce high quality systematic reviews, and various tools for systematic
processes. One such tool is their Assessment of Risk of Bias in Included Studies, which
has been implemented in RevMan, and described in Chapter 8.5 of the Cochrane
Handbook.98 This tool contains the seven categories that are assigned a judgement of
either ‘yes’ meaning that i.e. allocation concealment was adequately conducted and
there was a low risk of bias, “no” indicating a high risk of bias, or ‘unclear’ indicating that
the risk of bias was unknown.
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The first category is random sequence generation (selection bias). This requires
that allocating interventions to participants must be explicitly stated, and randomly
processed. This prevents the researchers from selecting what intervention the
participants receive.98 The second category is allocation concealment (selection bias).
For the study to be at low risk, the individual who is randomizing the participant must not
know what the next intervention allocation is. This prevents the individual randomizing
the participants from selecting who gets what intervention.98 The third category is
blinding of participants and personnel (performance bias), which occurs after the
participants have received their allocation. Blinding means that neither the researchers
or the participants are aware of which intervention they received. Blinding prevents
researchers from treating patients that received a certain intervention differently, and
vice-versa.98 The fourth category is blinding of outcome assessment (detection bias).
The outcome assessor must be blinded to the intervention when assessing outcomes
for the risk of bias to be low. For example, if a researcher knew what intervention was
given, and was recording subjective patient pain levels, they may rate the patient’s pain
higher or lower than what it truly is. Blinding prevents this type of bias from occurring.98
The fifth category is incomplete outcome data (attrition bias) – Attrition occurs from a
loss of participants. This can cause biased effect estimates and results. If a participant’s
data is available yet knowingly excluded from an analysis, bias occurs. Additionally, if
outcome data is not available (the participant dropped out, there was a nonresponse, or
withdrew), it can cause biased results.98 The sixth category is selection reporting
(reporting bias) – This occurs when researchers do not report all the study results. For
example, often only statistically significant results are reported, excluding the nonstatistically significant results from the publication. Finally, the last category is other
bias. Other biases can occur in specific circumstances. Recruitment bias, stopping a
study early, or having a sequence generation for allocation that may be predictable can
all contribute to bias.98
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CHAPTER 4

Methods

4.1. Methods Introduction
This review was conducted using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines107 (completed checklist in Appendix
A).

4.2. Search Strategy
A comprehensive search strategy was created to locate the maximum return of
relevant studies related to our question. Subject headings and keywords were tailored
to each of the electronic databases. The search strategy was performed in collaboration
with Dr. John Costella, a librarian with expertise in medical literature, and
ophthalmologists specializing in cataract extraction at St. Joseph’s Health Care in
London, Ontario. The terms listed in Table 4.1 were used to develop a comprehensive
search strategy with database and platform specific terminology and syntax for the
following databases: Medline (OVID), Embase (OVID), Cochrane Library (Wiley),
BIOSIS (Thomson-Reuters), Web of Science (Thomson-Reuters), and CINAHL
(EBSCO). Grey literature was explored by searching dissertations, theses, reports,
conference proceedings, clinical trials, as well as ophthalmology specific meeting
abstracts such as the Association for Research in Vision and Ophthalmology (ARVO),
Canadian Ophthalmology Society (COS), American Academy of Ophthalmology (AAO),
and European Society of Ophthalmology (SOE). The Conference Proceedings Citation
Index was also included as part of the Web of Science search. The appendix contains
the complete search strategies used for the included databases with a detailed list of
grey literature databases and websites explored (Appendix B). The original search was
performed on September 7th and 8th, 2016, with weekly publication notifications until
August 2017. To ensure all relevant studies were included, bibliographies of eligible
studies retrieved in the literature were hand searched.
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Table 4.1: Concepts, Keywords, and Phrases for Search Strategy
Concept
Cataract
Surgery

Subject Headings
Cataract Extraction, Cataract

Anesthesia

Neuroleptanalgesia, anesthesia,
local anesthesia, nerve block,
intravenous anesthesia,
cryoanesthesia, analgesia,
anesthetics, perioperative care,

Pain

Pain, eye pain, postoperative
pain, postoperative period,
postoperative care, perioperative
period, perioperative care,
intraoperative period,
intraoperative care
Intraoperative Complications/ or
Postoperative Complications/ or
Endophthalmitis/ or Keratitis/ or
Lens Subluxation/ or Retinal
Detachment/ or Vision Disorders/
or Eye Hemorrhage/ or Vitreous
Hemorrhage/ or Retinal
Hemorrhage/

Complications

Keywords
Phacoemulsification, cataract extraction,
cataract removal, cataract surgery,
cataract operation
Block, anesthesia, infiltration, injection,
orbicularis, subtenons, peribulbar,
retrobulbar, topical, Intracameral,
xylocaine, neuroleptics, benzodiazepine,
lidocaine, procaine, proparacaine,
oxybuprocaine, tetracaine, bupivacaine,
etidocaine, lidocaine, prilocaine,
ropicacaine, cryoanesthetics, midazolam,
fentanyl, propofol, perifentanyl, gravol,
dimenhydrinate, ondansetron, lorazepam,
Ativan, valium, diphenhydramine,
Benadryl
Pain, ache, discomfort, instillation, drop,
dilation, manipulation, freeze, pressure,
headache, postoperative, perioperative,
intraoperative.
Complication, broken capsule, posterior
capsule rupture, endophthalmitis,
keratitis, intraocular lens dislocation, lens
subluxation, low ocular pressure, ocular
hypotension, high ocular pressure, ocular
hypertension, anesthetic allergy, ocular
toxicity, or allergic reaction, vitreous
hemorrhage, or retinal detachment, or
choroidal hemorrhage, or suprachoroidal
hemorrhage, or ocular hemorrhage, or
eye hemorrhage, or retinal hemorrhage,
or systemic hypertension, vision loss,
vision disorder

4.3. Eligibility Criteria
With the expertise of ophthalmologists (WGH, CMLH) from the Ivey Eye Institute
in London, Ontario, the study’s eligibility criteria were established by identifying key
components that needed to be fulfilled to answer our research question: how different
anesthesia management strategies (IV vs non IV) in cataract extraction affect patient
pain perception and intra-operative adverse effects. The P.I.C.O.S. model for clinical
questions (patient, intervention, comparison, outcome, study design) was used.108 The
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P.I.C.O.S. tool allows researchers to focus their research on a specific question, and
determine specific exclusion and inclusion criteria that is used when selecting studies to
be included in the systematic review.
P.I.C.O.S. Tool
Participants: The study population included those with cataracts only and not cataracts
combined with other surgical conditions (see Table 4.2 for the list of surgeries that were
excluded). The included studies were also restricted to healthy adults (18+). This would
ensure homogeneity within the study.
Intervention: Interventions involve a wide range of exposures such as pharmaceutical
therapies, lifestyle changes, or social activities. In this study, the intervention was
intravenous conscious sedation on patient pain perception, and surgical complications
during phacoemulsification. Studies involving extracapsular cataract extraction (ECCE)
or Intracapsular cataract extraction (ICCE) were excluded
Comparator: The comparator was any anesthesia technique that did not use
intravenous sedation. This could include sublingual sedation, ocular blocks,
intracameral injections, topical anesthetics, or combinations thereof.
Outcomes: The primary outcomes were patient pain perception and perioperative
complications. These outcomes determine the effectiveness of the intervention and
comparator for patients undergoing cataract extraction. Both outcomes were analyzed
in a meta-analysis.
Study Design: Only randomized controlled trials were included in the study.
Observational studies (cohort, case-control, and cross-sectional) were excluded. Caseseries and case-reports were also excluded. Additionally, non-research articles such as
commentaries, editorials, letters, methodology papers, and review articles were
excluded.
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Inclusion Criteria:
Articles were included if they: (i) were from any country, (ii) in English (iii)
published from 1995 to present day (iv) were randomized control trials (v) had
intravenous therapy as the intervention (vi) had all other non-IV anesthesia and
sedation methods was the comparator (vii) had a study population of healthy adults with
cataracts undergoing phacoemulsification (viii) included outcome measures of interest –
pain perception, adverse complications or both.
Exclusion Criteria:
Articles were excluded if they: (i) were cohort, case-control, cross-sectional,
commentaries, editorials, letters, methodology papers, review articles (ii) were not in
English (iii) included patients who had combined surgical ocular conditions i.e. cataract
extraction and trabeculectomy (iv) included children (v) did not use phacoemulsification
as the surgery technique (vi) did not provide the outcome of interest (vii) were published
prior to 1995.
Rationale for Date Restriction
The exclusion criteria consisted of articles published prior to 1995 since
phacoemulsification is a relatively new procedure. It was not until 1967 that modern
phacoemulsification was invented by Charles Kelman at the Manhattan Eye, Ear, and
Throat Hospital in New York City. 46 However, even with the foundation of
phacoemulsification laid out, Kelman still had to overcome surgical, instrument, and
political problems before it would a widely performed procedure.69 In 1996, 97% of all
cataract operations in the United States were done by phacoemulsification. 48 For these
reasons 1995 was selected as a cut-off year.

4.4. Article Screening
Screening was performed at two levels (citations and full text) by two reviewers
(JJA and EK) to eliminate articles that did not meet the inclusion criteria. The screening
was done twice to ensure this process was conducted with the utmost accuracy, and to
reduce measurement bias. If a consensus was not reached during the article screening,
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then an experienced ophthalmologist (WGH) intervened to solve disagreements on
article eligibility. Level 1 consisted of simultaneously screening through titles and
abstracts to locate articles that were potentially relevant to the study question. The
screening questions for level 1 and 2 are listed in Table 4.2. If the answers to all the
questions were “do not exclude”, then the study would go on to level 2 screening.
Table 4.2: Study Eligibility Criteria
Level 1 Screening Questions (Title and Abstract)
*Covidence screening based on exclusion criteria

1) Exclude if the study does not look at uncomplicated cataract surgery in human adults.
2) Exclude if the cataract surgery performed is extracapsular extraction surgery (include
phacoemulsification only)
3) Exclude if the study is not measuring effectiveness of anesthesia modalities such as
sedation, intravenous therapy, blocks, topical drops, and local anesthesia.
4) Exclude if the study is not a primary study.
5) Exclude if the study is not in English.
6) Exclude if the study is not a comparative study.
Level 2 Screening Questions (Full Text)
*Covidence screening based on exclusion criteria

1) Exclude the study if it consists of the following combined ocular surgeries:
a. Combined cataract extraction and trabeculectomy
b. Combined cataract extraction and vitrectomy
2) Exclude if the study does not compare intravenous sedation to non-intravenous
sedation.
3) Exclude the study if it does not report on one of the following outcomes:
a. Pain
b. Complications
c. Adverse events

4.5. Data Extraction for Qualitative Data
Upon completion of the article screening, a data extraction form was created on
Microsoft excel. Two reviewers (EK and ST) independently extracted data using the
form. Authors were emailed to obtain any missing information that was relevant to the
study. The following information was collected in the final descriptive data extraction
form:
Study Characteristics: citation, study design, location. This gives an idea of the types of
studies being included in the analysis.
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Participant Characteristics: sample size, mean age (and standard deviation/range of
age if available), and the number of male and female patients. These characteristics are
necessary to be able to compare patients from different intervention groups
(intravenous sedation vs anesthetic techniques that did not use intravenous sedation).
Additionally, it allows us to determine if the patient populations were homogenous.
Treatment: type of surgery. It is important that all included studies treated patients with
the same surgery – phacoemulsification. This ensured homogeneity was present when
looking at different interventions.
Sedation/Anesthesia: sedation type (intravenous, sublingual, oral, or none), sedation
medication and dosage, topical anesthesia, gel anesthesia, and ocular/periocular
injections. This information was vital so that sedation management strategies could be
compared under the same surgical procedure.
Outcomes: The outcomes specifically looked at when comparing intravenous sedation
vs. anesthetic techniques that do not use intravenous sedation were pain perception
during surgery, and adverse events or complications that occurred perioperatively. For
pain preference, the following was recorded: the pain scale used, the result in each
group (mean, standardized difference, p-value), and the number of clinically-relevant
adverse events in each group, and a description of what the adverse events were.
These outcomes were extracted for the meta-analysis.

4.6. Data Extraction for Quantitative Data
Pain during surgical procedures is generally measured using a variation of pain
scales, such as the Visual Analogue Scale (VAS), Verbal Pain Scale (VPS), or a
Numeric Rating Scale (NRS). The mean and standard deviation of the pain levels in
each group was extracted. When studies did not directly report the mean pain or their
standard deviations, the authors were contacted. If the authors were unable to provide
data or did not respond, these values were extrapolated from the graphs within the

53

studies, or with imputation techniques described in Chapter 16.1 of the Cochrane
Handbook.98
Any adverse events or complications that occurred perioperatively were
extracted from the studies. This included the number of complications, the number of
patients who experienced complications, and a description of the adverse event. If
complications were not reported, authors were contacted for information.
In the instance where a study has more than two groups (intervention group 1,
intervention group 2, comparator group) the guidelines from Section 16.5 of the
Cochrane Handbook98 was used. The preferred methods of managing data from two
intervention groups is to either combine groups for a single pair-wise comparison, select
one intervention group and exclude the others, split the shared group to create two or
more comparison groups, or undertake a multiple-treatments meta-analysis.98

4.7. Risk of Bias in Included Studies
Bias in a study can be described as systematic error in the results of
interpretations. In other words, if a study with bias was repeated 1000 times in the exact
same way, the results would be incorrect most of the time.98 It is crucial to assess the
studies for bias in a systematic review. If the included studies prove to have a high risk
of bias, then the review’s conclusions and results will be weak or incorrect. However, if
there is a low risk of bias in the included studies, then the conclusions and results will
be strong and correct. Two reviewers (EK and ST) judged each study to be either at a
‘low’, ‘high’, or ‘un-clear’ risk for seven categories (see Section 3.15) using Cochrane’s
Assessment of Risk of Bias in Included Studies in Review Manager 5.3 (RevMan).
Disagreements were resolved through discussion, however if a consensus was not
reached, an experienced researcher (WGH) intervened to solve disagreements. When
an issue was ‘un-clear’, we would contact study authors for additional information. If
there was no response, we would assess the bias based on what information was
available. We used table 8.5.c in the Cochrane Handbook98 to guide our judgements, as
the criteria for correctly using their assessment tool is listed in detail.
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4.8. Risk of Bias versus Study Quality
As mentioned in section 4.7, bias refers to systematic error in the conclusions
and results of a study. Selection bias, performance bias, detection bias, attrition bias,
and reporting bias can all result in incorrect results and interpretations. When assessing
bias in a study, we are asking if the results of a study are true, and if we should believe
them. Study quality, on the other hand, refers to if the study was conducted at the
highest possible standard. This can refer to obtaining Research Ethics Board (REB)
approval, performing a sample size calculation, registering an RCT, or reporting a study
in line with recommendations such as the CONSORT109 (Consolidated Standards of
Reporting Trials) checklist or PRISMA107 (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines. An REB approval is unlikely to influence a
study’s risk of bias. Thus, risk of bias and study quality are distinctly different. For this
reason, we have also assessed the study quality using the GRADE110 (Grading of
Recommendations, Assessment, Development, and Evaluation) guidelines.

4.9. Assessing Study Quality using GRADE
The quality of evidence was assessed using the Grading of Recommendations,
Assessment, Development, and Evaluation guidelines.111–124 The GRADE working
group has created the GRADEpro tool on their website, allowing researchers to easily
summarize and assess articles using the GRADE quality assessment evidence profiles
and the Cochrane Summary of Findings tables. Two review authors (EK and ST)
independently assessed the quality of evidence using the GRADEpro tool.
Disagreements were resolved through discussion, however if a consensus was not
reached, an experienced researcher (WGH) intervened to solve disagreements. This
approach evaluates the overall quality of a body of evidence, assessing the risk of bias,
inconsistency, indirectness, imprecision, and publication bias. These five categories are
rated either as ‘not serious’, ‘serious’, or ‘very serious’, according to the reviewer’s
assessment, indicating any issues with the measurements. The articles published by
the GRADE working group give categories that were used to guide judgements. The
GRADEpro tool then summarized the ratings given on these five categories, and
assigned the article to be either low, moderate, or high quality evidence.
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4.10. Data Analysis
Primary Outcome – Pain Perception
Data analysis was conducted using STATA 13. In STATA, special syntax and
options were used to conduct a random effects meta-analysis, (metan) for one of the
primary outcomes – pain perception. All studies used meaningful scales, albeit with
slight variations. For this reason, a meta-analysis was performed on the standardized
mean difference. This is the standard method used when the included studies measure
the same outcome, but with a variety of continuous scales.125 This was conducted using
a random effects model, as it was anticipated that there would be excess heterogeneity
in the results due to the extensive variation of anesthetic techniques used in each study.
A sensitivity analysis was also conducted on the standardized mean difference to
examine the robustness of the results. For this method, we omitted studies with effect
sizes whose effect sizes were far from the rest of the data, and were clear outliers.
Often, outliers can amplify or diminish the mean of a sample, influencing the overall
treatment affect.126 Once the studies were omitted, the analysis was re-run with the
remaining studies. If the findings and conclusions were consistent with those from the
primary analysis, then the primary analysis is used. In this situation, the outlying studies
appear to have minimal impact on the primary conclusion, and the results are said to be
robust.126 Robust results can be described as strong results not affecting by outliers. A
second sensitivity analysis was conducted in which the studies that used imputation
techniques to estimate the missing standard deviations were omitted to investigate if
these methods had an impact on the overall effect size. In this situation, if the findings
are consistent with the primary analysis, then the results are said to be robust.
The results were also analyzed with a weighted mean difference meta-analysis.
This is conducted when the outcome is measured using the same units/scales in all
studies.125 For the analysis to be possible, the included studies were converted to the
same scale. This was done to highlight the clinical significance.
A sub-group analysis was conducted to identify differences in effect estimates in
certain subgroups. It is important to conduct subgroup analyses, as treatment effects
may vary according to intervention or patient characteristics. To determine the treatment
effect of different types of intravenous medication, a subgroup analysis was conducted.
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This analysis determined whether certain medications were more effective than others.
A second subgroup analysis was conducted to determine the effect of intravenous
sedation versus oral sedation. This analysis determined which sedation method was
most effective. In both subgroup analyses, a fixed effects model was used to yield better
precision, since it is assumed the subgroups are more homogenous.
A meta-regression was conducted to examine the relationship between certain
covariates and the effect size. The covariates used in this univariate random-effects
meta-regression to assess heterogeneity are as follows: location of study, year of
publication, sex, and mean age. This was done using STATA13 by creating new
variables that were coded to dichotomize the original data.127
Finally, a funnel plot was created using STATA13 to investigate publication bias.
Primary Outcome – Adverse Events
Data analysis was conducted using STATA 13. In STATA, special syntax and
options were used to conduct a random effects meta-analysis, (metan) for the second
primary outcome – adverse events and complications. This extracted data was utilized
for a dichotomous random effects meta-analysis. Data was collected as the number of
participants who experienced complications in each group, and the sample size. The
risk ratio was the effect measure calculated, which describes the probability that an
adverse event will occur with intravenous sedation, and non-intravenous sedation
techniques.
When conducting a meta-analysis of dichotomous outcomes, zero cells (when
there are no complications in one or both of the groups) do not allow the effect size to
be calculated, as computation problems arise.98 Since perioperative complications
during cataract surgery are not common, this potential problem was anticipated. A
correction factor of 0.5 was added to zero cells so effect sizes could be estimated for all
studies.
Finally, a funnel plot was created using STATA13 to investigate publication bias.
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CHAPTER 5

Results

5.1. Study Selection
A total of 4541 articles were retrieved by searching the previously mentioned
databases and grey literature, which were then imported into the Covidence screening
tool. After removing duplicate articles, 2920 articles were included for screening. The full
text of 428 articles were retrieved for level 2 screening. There were 10 articles eligible
for data extraction. The PRISMA diagram demonstrating the selection process is
displayed in Figure 5.1.
Figure 5.1: PRISMA Flow Diagram

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.
doi:10.1371/journal.pmed1000097
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5.2. Study Characteristics
A total of 4541 articles were retrieved from relevant databases and grey literature
searches. After level 1 and 2 screening, 1056,128–135 articles (985 participants) were
included for quantitative synthesis in the meta-analysis. Table 5.1, 5.2, and 5.3 depict
the baseline characteristics (demographic, intervention, and patient characteristics) of
each study. Studies were conducted in 6 different countries. All articles were published
between 2002 and 2015, and were randomized controlled trials. Of the 10 studies, 3
studies compared intravenous fentanyl to saline solution, 1 compared intravenous
midazolam to saline solution, 2 compared intravenous midazolam to an oral sedative, 1
compared intravenous clonidine to saline solution, 2 compared intravenous
dexmedetomidine to saline solution, and 1 compared intravenous remifentanil to saline
solution. There was variation in the methods used for mydriasis, topical anesthesia, and
ocular injection throughout the studies. There was no variation in study population; all
were adult cataract patients. For pain measurement, 3 studies used a numeric rating
scale (NRS) ranging from 0-10, 3 studies used a visual analogue scale ranging from 010, 2 studies used a visual pain scale ranging from 0-10, one study used a visual pain
scale ranging from 0-3, and one study used a 5 point likert scale. All pain scales used in
the randomized controlled trials have been validated.136–139 The main outcome
measures were pain perception and perioperative complications.
Table 5.1: Demographic Characteristics of Included Studies
Author (Year)

Location
128

Aydin et al. (2002)
129
Inan et al. (2003)
130
Laube et al. (2003)
131
Habib et al. (2004)
132
Leidinger et al. (2005)
133
Akgul et al. (2007)
134
Erdurmus et al. (2008)
135
Santiago et al. (2014)
56
Chen et al. (2015)
140
Ghodki et al. (2015)

Turkey
Turkey
Germany
England
Germany
Turkey
Turkey
Brazil
United States
India

Study
Design
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT
RCT

Sample Size

Population

68
120
97
100
90
120
44
40
156
60

Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
Adult cataract patients
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Table 5.2: Intervention Characteristics of Included Studies
Author
(Year)

Intravenous
Sedation Group

NonIntravenous
Sedation
Group
IV balanced
salt solution
PCA

Dilation Drops
(both groups)

Topical
Anesthetic (both
groups)

Ocular Injection
(both groups)

Aydin et al.
128
(2002)

IV fentanyl 0.7
µg/kg PCA

Cyclopentolate
hydrochloride 1%,
tropicamide 1%,
phenylephrine
hydrochloride 10%

n/a

IV fentanyl 2 µg/kg

IV of 500 cc
electrolyte
solution

Phenylephrine
hydrochloride
2.5%, tropicamide
0.5%,
cyclopentolate
hydrochloride 1%

Oxybuprocaine
hydrochloride
0.4%, sponge
soaked with
lidocaine 2% and
bupivacaine 0.5%
Proparacaine
hydrochloride

Inan et al.
129
(2003)

Laube et al.
130
(2003)

IV midazolam 1 mg

Oral
clorazepate
dipotassium
10mg

n/a

Habib et al.
131
(2004)

IV midazolam 0.015
mg/kg

IV cannula
inserted

n/a

Leidinger et
132
al. (2005)

IV remifentanil 0.3
µg/kg, Oral
clorazepate
dipotassium
IV fentanyl 0.7
µg/kg PCA OR
remifentanil 0.3
µg/kg PCA. Two
intervention groups
combined for a pairwise comparison
IV
dexmedetomidine 1
µg/kg

IV saline, Oral
clorazepate
dipotassium

n/a

n/a

IV saline

Cyclopentolate
hydrochloride 1%,
tropicamide 1%,
phenylephrine
hydrochloride 10%

n/a

IV saline

Santiago et
135
al. (2014)

IV clonidine 4µg/kg

IV saline

lidocaine 2% gel

n/a

Chen et al.
56
(2015)

IV midazolam 1.0
mg

Oral diazepam
5.0 mg

Diclofenac sodium
0.1%,
phenylephrine
hydrochloride
2.5%,
cyclopentolate 1%
phenylephrine
10%, tropicamide
1%
n/a

Oxybuprocaine
hydrochloride
0.4% drops, a
sponge soaked
with lidocaine 2%
and bupivacaine
0.5%
Proparacaine
0.5% drops

Ghodki et al.
140
(2015)

IV
Dexmedetomidine 1
mcg/kg

IV saline

Akgul et al.
133
(2007)

Erdurmus et
134
al. (2008)

*PCA = Patient controlled analgesia

n/a

n/a

Proxymetacaine
hydrochloride
0.5% drops

Tetracaine
hydrochloride 1%,
lidocaine
hydrochloride 2%
gel
Paracaine 0.5%

Retrobulbar block
mixture of 1 mL (5
mg/mL)
bupivacaine and
1.5 mL (20
mg/mL) of
lidocaine 2%
Retrobulbar block
of 6 to 8mL
mepivacaine
hydrochloride 2%
with 75 IE
hyaluronidase
Intracameral 1 to
2 mL
preservativefree lidocaine 1%
Retrobulbar nerve
block

n/a

Intracameral
preservative-free
lidocaine
hydrochloride
1.0%
n/a
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Table 5.3: Participant Characteristics of Included Studies
Author (Year)

Sample IV Sedation Group
Size
Male
Female Age (SD)
128

Aydin et al. (2002)
129
Inan et al. (2003)
130
Laube et al. (2003)
131
Habib et al. (2004)
132
Leidinger et al. (2005)
133
Akgul et al. (2007)
134
Erdurmus et al. (2008)
135
Santiago et al. (2014)
56
Chen et al. (2015)
140
Ghodki et al. (2015)

68
120
97
100
90
120
44
40
156
60

16
n/a
17
18
19
42
7
7
26
11

18
n/a
33
32
26
38
15
13
57
19

66.9 ±11.7
65.76 ±6.1
74 ±9.1
76.9 ±8.66
77 ±7.2
66 ±9.04
67.41 ±9.83
64.3 ±8.2
69
62.6 ±6.5

No IV Sedation Group
Male
Female
Age
19
n/a
18
25
23
22
8
9
35
10

15
n/a
29
25
22
18
14
11
38
20

67.8 ±9.4
65.21 ±7.82
72 ±12.6
79.31 ±7.05
77 ±7.5
68.6 ±8
69.46 ±9.99
65.5 ±10.7
69
61.4 ±6.9

5.3. Risk of Bias within Studies
Each study was thoroughly analyzed using the Cochrane risk of bias tool, and
the following figures were generated. Figure 5.2 is a risk of bias graph, demonstrating
what proportion of each study has a high, low, or unclear risk of bias. Figure 5.3 is a risk
of bias summary; the judgements are shown in cross-tabulation.
In conclusion, eight studies had a low risk of bias, meaning that bias is unlikely to
seriously alter the results of the studies. One study had an unclear risk of bias; it is
possible that there may be some skepticism regarding the results. Lastly, one study had
a high risk of bias; the result and interpretations may have been affected in this study.
The bias across studies was mainly present in allocation concealment. However, we do
not believe that this may have affected the outcome or results in a significant way. Thus,
all studies were included in the statistical analysis, comparing intravenous sedation to
non-intravenous techniques in cataract extraction.
Figure 5.2: Risk of Bias Graph (Percentages across all included studies)
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Figure 5.3: Risk of Bias Summary

5.4. GRADE Quality Assessment
The quality of the studies included in the systematic review were analyzed using
the GRADE guidelines. The results indicate that eight articles were high quality, and two
articles were moderate quality (Table 5.4). All articles were included in the analysis,
which compares intravenous sedation to non-intravenous anesthesia techniques in
cataract extraction.
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Table 5.4: GRADE Evidence Profile
Study
Aydin et al.
128
(2002)
Inan et al.
129
(2003)
Laube et al.
130
(2003)
Habib et al.
131
(2004)
Leidinger et
132
al. (2005)
Akgul et al.
133
(2007)
Erdurmus et
134
al. (2008)
Santiago et al.
135
(2014)
Chen et al.
56
(2015)
Ghodki et al.
140
(2015)

Risk of
Bias
Not
serious
Serious

Inconsistency

Indirectness

Imprecision

Not serious

Not serious

Not serious

Publication
Bias
None

Not serious

Not serious

Not serious

None

Serious

Not serious

Not serious

Not serious

None

Not
serious
Not
serious
Not
serious
Not
serious
Not
serious
Not
serious
Not
serious

Not serious

Not serious

Not serious

None

Not serious

Not serious

Not serious

None

Not serious

Not serious

Not serious

None

Not serious

Not serious

Not serious

None

Not serious

Not serious

Not serious

None

Not serious

Not serious

Not serious

None

Not serious

Not serious

Not serious

None

Overall Quality
of Evidence
⨁⨁⨁⨁
HIGH
⨁⨁⨁◯
MODERATE
⨁⨁⨁◯
MODERATE
⨁⨁⨁⨁
HIGH
⨁⨁⨁⨁
HIGH
⨁⨁⨁⨁
HIGH
⨁⨁⨁⨁
HIGH
⨁⨁⨁⨁
HIGH
⨁⨁⨁⨁
HIGH
⨁⨁⨁⨁
HIGH
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5.5. Primary Outcome – Pain
This section will be an overview on the analysis of pain perception when
comparing intravenous sedation to non-intravenous techniques.

5.5.1. Data Extraction and Imputation
The sample size, mean, and standard deviations required for the meta-analyses
were extracted from each study and are depicted in Table 5.5. Four studies had missing
standard deviations. Although it is best to avoid using imputation techniques, it is often
the only way to combine data with other studies. Before imputation was considered for
the following studies, corresponding authors were contacted for more information and
data. However, most of the authors did not get back to us, and those who did no longer
had the data for the study of interest. For this reason, the standard deviations for the 4
studies were imputed using standard errors, confidence intervals, student’s t values,
and P values. When the articles were limited to the median, interquartile range, or
range, the distribution was assumed to be normal and the SD was estimated. These
methods are further described in the Cochrane Handbook98. If the statistics listed above
were not available in the article, the standard deviations were imputed using novel
methods. A detailed description of the calculations involved for the imputations in this
study is listed in Appendix C.
Table 5.5: Extracted Data for Meta-Analysis
Author (Year)

Pain Scale
128

Aydin et al. (2002)
129
Inan et al. (2003)
130
Laube et al. (2003)
131
Habib et al. (2004)
132
Leidinger et al. (2005)
133
Akgul et al. (2007)
134
Erdurmus et al. (2008)
135
Santiago et al. (2014)
56
Chen et al. (2015)
140
Ghodki et al. (2015)

VPS (0-10)
VPS (0-3)
Likert Scale (0-4)
VAS (0-10)
VAS 0-10
VPS (0-10)
VAS (0-10)
NRS (0-10)
NRS 11 (0-10)
NRS (0-10)

Intravenous Sedation
Sample Mean
SD
Size
34
0.52 §
± 1.11 *
60
0.08
± 0.27
50
0.18
± 0.44
50
0.29
± 0.65*
45
2.58 §
±1.06 §
80
0.25
± 0.80*
22
1.23
± 1.72
20
0.81
±1.41
83
0.072
± 0.38
30
3
± 0.29*

*NRS = Numerical rating scale, VAS = Visual analogue scale, VPS = Verbal pain scale

§= extracted from graph or figure
*=imputed

Non-Intravenous Group
Sample Mean
SD
Size
34
1.16 § ± 1.11 *
60
1.06
± 0.25
47
0.13
± 0.61
50
0.38
± 0.59 *
45
5.53 § ± 2.06 §
40
0.7
± 0.80*
22
3.64
± 1.43
20
1.57
± 1.82
73
0.082
± 0.40
30
3
± 0.29*
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5.5.2. Meta-Analysis – Standardized Mean Difference
Figure 5.4 below displays the forest plots of random effects pooled meta-analysis
of the weighted standardized mean difference. The total sample size was 895 patients
across all 10 analyzed studies. In the pooled random effects analysis, intravenous
sedation was significantly associated with a decrease in pain (SMD = -0.86 with 95% CI
of -1.49 to -0.23, p=0.0008) and the I2 was 94.8%, p=0). It may be worthwhile to note
that 7 studies (70%) reported that intravenous sedation significantly reduced pain
perception. Stata code used is available in Appendix D.
Figure 5.4: Pooled random effects meta-analysis for pain perception (SMD)

65

5.5.3. Sensitivity Analysis
Although the included studies appear to be robust due to the narrow confidence
intervals, the I2 and p-value suggests there is considerable heterogeneity. Of the ten
included studies, two studies129,132 had effect sizes that were much larger than the rest.
These studies were removed to conduct a sensitivity analysis. The adjusted forest plot
for standardized mean differences is displayed in Figure 5.5 below. In the sensitivity
analysis, intravenous sedation was still significantly associated with a decrease in pain
(SMD = -0.35 with 95% CI of -0.65 to -0.05, p=0.021) and the I2 was 71.3%, p=0.001.
Even when the two outlier studies are excluded, the result is still the same; intravenous
sedation significantly reduces pain perception, when compared to non-intravenous
methods.
Figure 5.5: Sensitivity Analysis – Exclusion of Outlier Studies
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A second sensitivity analysis was performed. Here, the studies in which
imputation techniques were used to estimate the mean or standard deviation were
omitted to investigate if the imputation methods had an impact on the overall effect size.
Four studies131,133,141,142 were excluded for the sensitivity analysis. The adjusted forest
plot for standardized mean differences is displayed in Figure 5.6 below. In the sensitivity
analysis, intravenous sedation was still significantly associated with a decrease in pain
(SMD = -1.24 with 95% CI of -2.34 to -0.13, p=0.028) and the I2 was 96.8%, p=0. Even
when four studies with imputation techniques are excluded, the result is still the same;
intravenous sedation significantly reduces pain perception, when compared to nonintravenous methods. This sensitivity analyses suggests that the effects of pain
perception are robust across the imputation techniques used for missing standard
deviations.
Figure 5.6: Sensitivity Analysis – Exclusion of Imputation Methods
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5.5.4. Meta-Analysis – Weighted Mean Difference
A weighted mean difference meta-analysis was also conducted. The included
studies were converted to the same scale for this analysis. Figure 5.7 below displays
the forest plot of random effects pooled meta-analysis of the weighted mean difference
in pain perception, where a negative change is a reduction of pain perception using
intravenous sedation, and a positive change is a reduction of pain perception using nonintravenous sedation methods. A weighted mean difference was calculated to highlight
the clinical significance of the results. In the pooled random effects meta-analysis,
intravenous sedation was significantly associated with a decrease in pain (WMD= -1.01
with 95% CI of -1.66 to -0.36, p=0.002) and the I2 was 98.1%, p=0. Overall, intravenous
sedation reduced pain by 1.01 units on the 10-unit pain scale, when compared to nonintravenous anesthesia methods. This can be interpreted as a 10.1% decrease in pain.
Figure 5.7: Pooled random effects meta-analysis for pain perception (WMD)
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5.5.5. Sub-group Analysis by Intervention Sedation
The first fixed effects sub-group analysis was grouped by the intravenous
medication used in the intervention groups. Two studies that used intravenous fentanyl
as the intervention sedative indicated that patients did have a statistically significant
reduction in pain, with a SMD of -1.84 (95% CI -2.22 to -1.46, p=0, i2=98.5%). Three
studies that used intravenous midazolam as the intervention sedative indicated that
patients did not have a statistically significant reduction in pain, with a SMD of -0.03
(95% CI -0.24 to 0.18, p=0.804, i2=0%). One study that used intravenous remifentanil as
the intervention sedative indicated that patients did have a statistically significant
reduction in pain, with a MD of -1.80 (95% CI -2.29 to -1.31, p=0). Since there is only
one study in this subgroup, heterogeneity calculation is not possible. One study used
both intravenous fentanyl and intravenous remifentanil as the intervention sedatives.
The subgroup analysis indicates that patients did have a statistically significant
reduction in pain, with a MD of -0.56 (95% CI -0.95 to -0.18, p=0.004). Since there is
only one study in this subgroup, heterogeneity calculation is not possible. Two studies
that used intravenous dexmedetomidine as the intervention sedative indicated that the
patients did have a statistically significant reduction in pain, with a SMD of -0.55 (95%
CI -0.95 to -0.14, p=0.0.008, i2=92%). Lastly, one study that used intravenous clonidine
as the intervention sedative indicated the patients did not have a statistically significant
reduction in pain, with a MD of -0.47 (95% CI -1.10 to 0.16, p=0.146). This forest plot is
graphically displayed in Figure 5.8.
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Figure 5.8: Sub-group Analysis of Intervention Group by Intravenous Sedation
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5.5.6. Sub-group Analysis by Non-Intravenous Sedation Method
The second fixed effects sub-group analysis is grouped by the non-intravenous
sedation method used in the comparator group. Eight studies used a placebo saline
drip, with various topical and injection anesthesia strategies (see Table 5.2 for
anesthesia characteristics) as the comparator against an intravenous sedation strategy.
The sub group analysis indicated that the patients did have a statistically significant
reduction in pain when using intravenous sedation; a saline drip with topical and / or
ocular injections did not control pain perception as well as intravenous sedation. The
SMD was -0.90 (95% CI -1.07 to -0.72, p=0, i2= 94.9%).
Two studies used an oral sedative, with various topical and injection anesthesia
strategies (Table 5.2) as the comparator to an intravenous sedation method. The sub
group analysis indicated that the patients did not have a statistically significant reduction
in pain when using intravenous sedation over oral sedation. The SMD was 0.02 (95% CI
-0.23 to 0.27, p=0.871, i2=0%). Thus, when comparing intravenous sedation to oral
sedation, they appear to be equivalent in terms of pain control. This is displayed in
Figure 5.9.
Figure 5.9: Sub-group Analysis of Comparator Group by Non-IV Methods

71

5.5.7. Meta-regression
A meta-regression recognizes the reasons for heterogeneity and possible
explanations for it in a meta-anlaysis.125 A meta-regression examines the extent to
which heterogeneity between results of multiple studies can be associated to
characteristics of the studies. Since heterogeneity was present in the pooled metaanalysis, a univariate random effects meta-regression was conducted. The results can
be found in Table 5.6. The covariates that were examined were the location of the
study, year of publication, sex of participants, and the mean age of participants. Exact
descriptions of how they were dichotomized are found in Table 5.6. No covariates were
found to be significant, and heterogeneity was found in all covariates.
Table 5.6: Random Effects Meta-Regression Results
Metaregression
on:
Location
of Study
Year of
study
Mean Age
Male/
Female

2

Adjusted R

2

Tau

2

Covariate

Regression
Coefficient (95% CI)

P-value

I

North America (1) vs.
Other (0)
After 2005 (1) vs.
before or on 2005 (0)
Greater than or equal
to 70 (1) vs. less than
70 years old (0)
Higher proportion of
males (1) vs. higher
proportion of females
(0)

0.94 (-2.01 to 3.88)

0.485

94.90%

-6.06%

1.425

0.71 (-1.03 to 2.47)

0.374

94.98%

-1.56%

1.365

0.36 (-1.62 to 2.35)

0.683

95.32%

-10.90%

1.49

-0.42 (-1.39 to 1.31)

0.944

87.72%

-17.22%

0.45
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5.5.8. Funnel Plot
Funnel plots are a visual display that can be used to assess if the results of a
meta-analysis are affected by bias and heterogeneity. In the absence of bias and
heterogeneity, 95% of the included studies are expected to lie within the dashed
triangular lines. The funnel plot for the studies included in the analysis of the pain
perception in cataract extraction is displayed in Figure 5.10. The asymmetry of the
funnel plot indicates the presence of publication bias and heterogeneity; on the left side,
there are three studies that are widely scattered on the bottom of the triangle, and on
the right side there are seven studies that are clustered together but still extended
around the middle area of the triangle, closer to the center. As a trial’s sample size
increases, the precision of the effect estimate increases as well. Large, precise studies
will localize to the top of the funnel plot, whereas small imprecise studies will have effect
estimates that scatter widely at the bottom of the plot.143 This premise supports the
funnel plot depicted below, as all the included studies had a small number of
participants, and the effect estimates are widely scattered across the bottom half of the
funnel plot.
Figure 5.10: Funnel Plot for Pain Perception
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5.6. Primary Outcome – Complications
This section will be an overview on the rate of adverse events when comparing
intravenous sedation to non-intravenous techniques. Table 5.7 lists the quantitative data
extracted from each study for analysis.
Table 5.7: Quantitative Data for Meta-Analysis
Author (Year)

130

50

11

4 patients with
posterior capsule
rupture
3 patients with anterior
vitrectomy
4 patients with sulcus
fixation of IOL

131

50
45

0
7

n/a
3 patients with
bradycardia
3 patients with nausea

Non-IV Sedation Methods
Patients with Complications
Sample # Description
Size
34
0 n/a
60
5 5 patients with
systemic
hypertension
requiring an antihypertensive drug
47
7 2 patients with
posterior capsule
rupture
1 patient with
bleeding
2 patients with
anterior vitrectomy
2 patients with sulcus
fixation of IOL
50
0 n/a
45
2 1 patient with
tachycardia
1 patient with nausea

1 patient with
intraoperative
sweating
n/a
n/a
n/a
n/a
n/a

40
22
20
73
30

128

Aydin et al. (2002)
129
Inan et al. (2003)

Laube et al. (2003)

Habib et al. (2004)
132
Leidinger et al. (2005)

133

Akgul et al. (2007)
134
Erdurmus et al. (2008)
135
Santiago et al. (2014)
56
Chen et al. (2015)
140
Ghodki et al. (2015)

Intravenous Sedation
Patients with Complications
Sample
#
Description
Size
34
0
n/a
60
0
n/a

80
22
20
83
30

0
0
0
0
0

0
0
0
0
0

n/a
n/a
n/a
n/a
n/a
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5.6.1. Meta-Analysis
Figure 5.11 displays the forest plot for the meta-analysis for risk of complications.
The total sample size was 895 patients across 10 analyzed studies. 18 patients in the
intravenous sedation group had perioperative complications, and 14 in the nonintravenous sedation methods group had perioperative complications. It was found that
intravenous sedation did not significantly increase complications (RR= 0.98 with 95% CI
0.92 to 1.05, p=0.614, i2=75.6%). A risk ratio of 1 indicates that there is no difference in
risk between the two groups. Stata code used is available in Appendix D.
Figure 5.11: Meta-Analysis for Risk of Complications
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Since 7 studies were excluded due to having 0 cell counts, we decided to add in
a correction factor of 0.5 examine how the results may be affected (somewhat of a
sensitivity analysis). Figure 5.12 displays the forest plot for the risk of complications with
the correction factor. It was found that intravenous sedation did not significantly
increase complications (RR= 0.99 with 95% CI 0.97 to 1.02, p=0.704, i2=0%). A risk
ratio of 1 means there is no difference in risk between the two groups. The results of the
meta-analysis with the correction factor are almost indistinguishable, showing that a
directional bias was not introduced with the correction.
Figure 5.12: Meta-Analysis for Risk of Complications with Correction Factor
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5.6.2. Funnel Plot
Funnel plots are a visual display that can be used to assess if the results of a
meta-analysis are affected by publication bias and/or heterogeneity. The funnel plot for
the risk of complications is displayed in Figure 5.13. This funnel plot appears to be
nearly symmetrical (as can be seen from the lack of studies in the lower right quadrant),
suggesting the presence of a small amount of potential publication bias. Possible
explanations for this asymmetry include language bias (only English articles were
included), small numbers of participants in the included randomized controlled trials,
imprecise effect, and lastly, the asymmetry may simply be due to chance.
Figure 5.13: Funnel Plot of Risk of Complications
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CHAPTER 6

Discussion

6.1. Overview
The final chapter of this document will outline the results, interpretations, and
conclusions. In summary, the objectives of this thesis were to (1) determine the level of
patient pain perception associated with cataract extraction by phacoemulsification,
when administered under intravenous sedation versus non-intravenous anesthesia
techniques and (2) determine the complication rate perioperatively when the patient is
under intravenous sedation versus non-intravenous anesthesia techniques.

6.2. Systematic Review
This is the first study to conduct a systematic review and meta-analysis on the
effects of intravenous sedation versus non-intravenous sedation methods during
cataract extraction. There were 4541 citations and full texts screened using the
P.I.C.O.S. model98 and inclusion/exclusion criteria. There were 10 studies included in
the review upon completion of level 1 and level 2 screening. They were found to be of
high quality of evidence according to the GRADE tool, and to be at low risk of bias
according to Cochrane’s Assessment of Risk of Bias in Included Studies. There were
895 patients overall.
The patient characteristics were similar among the studies. All participants were
adult patients (~65 years of age) undergoing phacoemulsification (Table 5.1 and Table
5.3). However, the study characteristics varied (Table 5.2). The sedation strategy and
anesthesia techniques and pharmaceuticals differed in each study; each clinic had their
own methods of achieving sedation and ocular anesthesia (whether that be with topical
drops, topical gel, or ocular injections). Additionally, there was slight variations in the
pain scale utilized. The intervention groups in the included studies varied with regards to
the intravenous sedative used; intravenous fentanyl, midazolam, remifentanil,
dexmedetomidine, clonidine, and a combination of fentanyl and remifentanil were used.
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6.3. Meta-Analysis and Subgroup Analysis
Pain Perception
There were 10 studies included in the meta-analysis that compared pain
perception under intravenous sedation and non-intravenous sedation methods during
cataract extraction. Since standard deviations were not reported in four of the studies,
imputation techniques were used to estimate the missing values, allowing the studies to
be included in the analysis.
Results from the standardized mean difference meta-analysis indicate that
intravenous sedation significantly reduces pain during cataract extraction (SMD= -0.86,
95% CI of -1.49 to -0.23, p=0.0008). A weighted mean difference meta-analysis was
also conducted to highlight the clinical significance of this finding. The results indicate
that intravenous sedation reduced pain by 1.01 unit on a 10-unit pain scale, when
compared to non-intravenous sedation methods. This can be translated to an
approximate 10% decrease in pain with IV sedation techniques.
Sensitivity analyses were conducted to ensure that the study results were robust.
The first sensitivity analysis consisted of removing two outlier studies; the result
remained the same. Intravenous sedation significantly reduced pain even when the two
studies with the greatest variation were removed from the analysis. The second
sensitivity analysis consisted of removing four studies with standard deviations that
were estimated with imputation techniques. The overall effect size remained
homogenous with the primary analysis; intravenous sedation was still significantly
associated with a decrease in pain (SMD = -1.24 with 95% CI of -2.34 to -0.13,
p=0.028). The sensitivity analysis suggests that the results from the primary analysis
are robust. Although there was considerable heterogeneity in the primary analysis, the
robustness of the sensitivity analysis and the narrow confidence intervals indicate that
the combination of these studies for a meta-analysis is valid. Further, a meta-regression
was conducted with the prospect of better understanding the heterogeneity. The
covariates that analyzed were study location, study year, age, and sex. After running
the meta-regression, none of the covariates were found to be significantly associated
with a change in effect size. It is presumed that the heterogeneity in the study is due to
the variation in anesthesia and sedation techniques found between the studies.
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The first subgroup analysis conducted was a fixed-effects meta-analysis by
intervention sedative. The purpose of this sub group was to establish which medication
was most effective at reducing pain during phacoemulsification. The results indicate that
intravenous fentanyl (SMD of -1.84,95% CI -2.22 to -1.46, p=0), intravenous remifentanil
(MD of -1.80,95% CI -2.29 to -1.31, p=0), intravenous fentanyl/remifentanil (MD= -0.56,
95% CI -0.95 to -0.18, p=0.004), and intravenous dexmedetomidine (SMD of -0.55, 95%
CI -0.95 to -0.14, p=0.0.008) significantly reduced pain during phacoemulsification,
while intravenous clonidine and midazolam did not significantly reduce pain more than
the non-intravenous sedation techniques. This has potential to impact cataract
ambulatory care. For clinics that use intravenous sedation and will continue to do so,
changing the intravenous sedative to one of the above medications that are more
effective at reducing pain can benefit the patient experience.
The second subgroup analysis conducted was a fixed effects meta-analysis that
examined the sedation technique of the comparator group. There were two subgroups
created during this analysis. One subgroup compared placebo saline with various
anesthetic methods to intravenous sedation, and the second subgroup compared oral
sedation to intravenous sedation. The first subgroup (placebo saline versus intravenous
sedation) indicated that patients have a statistically significant reduction in pain when
using intravenous sedation; a saline drip with topical and / or ocular injections does not
control pain perception as well as intravenous sedation (SMD= -0.90, 95% CI -1.07 to 0.72, p=0). The second subgroup (oral sedation versus intravenous sedation) indicated
that oral sedation and intravenous sedation techniques were equivalent in pain control
(SMD= 0.02, 95% CI -0.23 to 0.27, p=0.871). These results have potential to impact
resource allocations in both publicly and privately funded environments, particularly the
second subgroup analysis which compares oral sedation to intravenous sedation. The
introduction of intravenous sedation requires tremendous resources; equipment,
medication, nurse anesthetists, and the presence of anesthesiologist. A cost analysis
study published in 200110 found that oral sedation cost $16.47 per procedure, while
intravenous sedation could cost up to $324.72 per procedure; intravenous sedation was
19x more expensive than oral sedation in 2001. There is no doubt that the cost of
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intravenous sedation in 2017 has increased with the cost inflation of equipment,
medications, and personnel.
There are limitations associated with these subgroup analyses. First, subgroup
analyses are entirely observational since they are not based on the pre-specified
randomized comparisons (intravenous sedation versus non-intravenous sedation
methods). Next, there were a few studies in each of the subgroups. Smaller numbers of
studies may result in a less precise summary effect size. Specifically, there were only
two studies that compared intravenous sedation to oral sedation. For this reason, we
recommend further research in this area so that a more precise summary effect
estimate can be determined.
Adverse Events
There were 10 studies included in the meta-analysis that compared the number
of patients with adverse events under intravenous sedation and non-intravenous
sedation methods during cataract extraction. There were 18 patients in the intravenous
sedation group that had perioperative complications, and 14 in the non-intravenous
sedation methods group that had perioperative complications. Many of the included
studies had no adverse events or complications occur during the trial, resulting in many
zero cells in the analysis. For this reason, two meta-analyses were conducted. The first
meta-analysis included the three studies in which adverse events occurred. The results
indicated that there was no difference in risk between the two groups (RR= 0.98 with
95% CI 0.92 to 1.05, p=0.614, i2=75.6%). The second meta-analysis was conducted
with a correction factor of 0.5 added into the zero cells. The results indicated again that
there was no difference in risk between the two groups (RR= 0.99, 95% CI 0.97 to 1.02,
p=0.704). The nearly identical results indicate robustness in the analysis. To reiterate
the cost summary above, in 2001 it was found that intravenous sedation could cost
upwards of $324.72 per procedure, 19x more expensive than non-intravenous
sedation.10 The risk ratio of intravenous sedation versus non-intravenous sedation
should be considered by anesthesiologists and surgeons when determining which
anesthesia/sedation technique to utilize. Since there is not an increase in risk with non-
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intravenous sedation techniques, and it is a far more economical option, it is evident
that using non-intravenous sedation strategies is a feasible option.

6.4. Publication Bias
The funnel plot for pain perception is displayed in Figure 5.10. The presence of
asymmetry in this funnel plot is evident, indicating publication bias. The funnel plot for
the risk of complications is displayed in Figure 5.13. This funnel plot appears to be
nearly symmetrical (as can be seen from the lack of studies in the lower right quadrant).
There are several possibilities to explain the funnel plot’s asymmetry. First, language
bias was present, as the search strategy was limited to English articles. Second,
publication bias may be present. A study which reviewed publication bias from the
Cochrane database of systematic reviews found that when a meta-analyses of efficacy
was conducted, outcomes that were statistically significant were 27%144 more likely to
be included in the review. Further, it has been reported that statistically significant
results are three times more likely to be accepted for publication than papers with nonsignificant results.145 Third, the funnel plot may be asymmetrical simply due to chance.
Fourth, all the included studies were small randomized controlled trials with a range of
40 to 156 participants. It is possible that these studies were conducted with less
methodological rigor than larger scale randomized controlled trials resulting in imprecise
effect estimates.103–105 Lastly, we know from the meta-analysis conducted that
heterogeneity is present, which may cause the funnel to be asymmetrical. Funnel plots
are not without their limitations. Since funnel plots are purely visual and not a statistical
test, their interpretations are subjective, especially when there are few studies. They do
not accurately predict publication bias146, therefore treatment decisions should not be
based on the symmetry of a funnel plot.

6.5. Limitations
In our inclusion/exclusion criteria, one of the components was to limit the
included studies to English speaking articles only, since we did not have translational
services available. This could be a factor that resulted in the presence of publication
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bias in our study, as displayed by the funnel plot for pain perception (Figure 5.7). It is
recommended that future reviews attempt to include non-English articles.
Another limitation was insufficient data reported in the included articles. Four of
the articles did not have standard deviations explicitly stated, and even though authors
were contacted for original datasets and information, none were provided. The standard
deviations were generated via imputation techniques to make meta-analysis possible.
However, this can be a risky process because assumptions are being made about the
data, which could result in bias or narrow confidence intervals.98 It is recommended that
more trials are done comparing intravenous sedation to non-intravenous sedation
techniques, and that the authors publish complete data with respect to effect sizes.
Many researchers agree that only two studies147 are required for a meta-analysis,
however the Cochrane Handbook98 states that the minimum number of studies in a
meta-analysis should be 10. More studies result in smaller confidence intervals and
higher statistical power, and less studies in a review may introduce bias. It is therefore a
limitation that this systematic review and meta-analysis is comprised of 10 studies. This
can be viewed as an opportunity for future research to expand the body of knowledge in
this topic area.
Lastly, there was considerable heterogeneity present in all the analyses.
However, the sensitivity analyses conducted demonstrates that the results are robust,
and even when outlier studies are removed, or studies whose statistics have been
estimated with imputation techniques are removed, the conclusion remains the same.
Additionally, the confidence intervals of the included studies are narrow, implying that
the accuracy is also high. The presence of heterogeneity is likely from the variation of
the intravenous sedative used in the included studies, and the variation in the nonintravenous anesthesia techniques. It would be extremely difficult to find studies with
homogenous sedation and anesthesia techniques, as there are no guidelines currently
available with recommendations on which methods to use. The sedation and anesthesia
techniques rely solely on the preference of the operating surgeon or overseeing
anesthesiologist.
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6.6. Strengths
A meta-analysis is a powerful statistical procedure that allows research to
combine all the information present on a topic or research question, and investigate the
discrepancies between their results. This tool allows the researcher to calculate a single
effect estimate, allowing professionals in health care, medicine, and other fields to
generalize the results to a larger population and use evidence based medicine.
However, utmost care must be taken when performing a meta-analysis; if conducted
with even the slightest mistake, or error in methodology, it can result in incorrect,
biased, or misleading results. When conducted this systematic review and metaanalysis, we adhered to every guideline available. The Cochrane Handbook and
PRISMA checklist was referred to at every step in the process; search strategy
formulation, article extraction from databases, screening, data extraction, quality
assessment, and analysis. A strength of this study is unquestionably the high standards
of methodological rigor that was upheld.
Another strength of this systematic review and meta-analysis is the study design
of the included studies. All included studies are randomized controlled trials. RCT’s by
nature are of higher quality, and contain less bias than other study designs. The
observed effect size of an RCT will generally be closer to the true effect size than an
observational study, for example. Since all studies are RCT’s, the summary effect
estimate will have high accuracy and precision, ensuring the integrity of the results.
The studies were evaluated on quality and risk of bias using the GRADE tool and
Cochrane’s Risk of Bias tool. The two reviewers determined with the GRADEpro tool
that 8 studies were of high quality, and two were of moderate quality. The Cochrane
bias tool determined that there were eight studies were a low risk of bias, and two with a
high risk of bias. These results suggest that the overall quality of the included studies
was high, which increases the validity of the results.
Lastly, this was the first meta-analysis done to address the question of
intravenous sedation versus non-intravenous sedation. Articles were collected from 6
databases and grey literature searches using a meticulous search strategy created with
the help of an information technician. Strict inclusion and exclusion criteria were
adhered to, ensuring all relevant articles were obtained. Since this review was
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completed with such rigorous attention to detail, we feel it is a valuable addition to the
literature, that will inspire future research in this topic area.

6.7. Recommendations for Future Research
Future research should focus on examining the effectiveness of intravenous
sedation versus oral sedation, as there is insufficient research in this area. In this
systematic review and meta-analysis, there were only two randomized controlled trials
that evaluated this relationship. Oral sedation appears to be just as effective at
controlling pain as intravenous sedation, is significantly less costly, and does not appear
to have any associated increases in complications. Investigating the effects of oral
sedation during phacoemulsification may benefit the allocation of resources in both
publically and privately funded clinics. In addition to randomized controlled trials that
evaluate the effects of oral sedation, future studies should also survey patient’s
preferences regarding sedation methods during cataract extraction. An updated costanalysis model to reflect the cost of intravenous sedation versus oral sedation in
present time will also be of great value to the literature. Finally, future research should
focus on creating guidelines and recommendations for anesthesia and sedation
strategies in North America.

6.8. Conclusion
This systematic review was conducted with the utmost accuracy and
methodological rigor. The results indicate that intravenous sedation is more effective at
controlling patient pain compared to non-intravenous sedation methods. Subgroup
analysis indicated that oral sedation and intravenous sedation techniques were
equivalent in controlling patient pain. The rate of adverse events was found to be
equivalent in both sedation groups. This thesis has identified crucial gaps in the
literature, which will guide future research, allowing us to generate better conclusions
regarding the most effective sedation method for phacoemulsification.
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Appendices
Appendix A: Preferred Reporting Item for Systematic Reviews and Meta-analysis
(PRISMA) guidelines
Section/topic
TITLE
Title
ABSTRACT
Structured
summary

# Checklist item

Reported
on page #

1 Identify the report as a systematic review, meta-analysis, or
both.

i

2 Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility
criteria, participants, and interventions; study appraisal and
synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration
number.

ii

INTRODUCTION
Rationale
3 Describe the rationale for the review in the context of what is
already known.
Objectives
4 Provide an explicit statement of questions being addressed
with reference to participants, interventions, comparisons,
outcomes, and study design (PICOS).
METHODS
Protocol and
5 Indicate if a review protocol exists, if and where it can be
registration
accessed (e.g., Web address), and, if available, provide
registration information including registration number.
Eligibility
6 Specify study characteristics (e.g., PICOS, length of followcriteria
up) and report characteristics (e.g., years considered,
language, publication status) used as criteria for eligibility,
giving rationale.
Information
7 Describe all information sources (e.g., databases with dates
sources
of coverage, contact with study authors to identify additional
studies) in the search and date last searched.
Search
8 Present full electronic search strategy for at least one
database, including any limits used, such that it could be
repeated.
Study selection
9 State the process for selecting studies (i.e., screening,
eligibility, included in systematic review, and, if applicable,
included in the meta-analysis).
Data collection
10 Describe method of data extraction from reports (e.g.,
process
piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from
investigators.
Data items
11 List and define all variables for which data were sought
(e.g., PICOS, funding sources) and any assumptions and
simplifications made.
Risk of bias in
12 Describe methods used for assessing risk of bias of
individual
individual studies (including specification of whether this
studies
was done at the study or outcome level), and how this

5-6
49

-49-50

47
101-108
50-51
51

51-52
54

101

information is to be used in any data synthesis.
Summary
measures
Synthesis of
results

13 State the principal summary measures (e.g., risk ratio,
difference in means).
14 Describe the methods of handling data and combining
results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.
15 Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g., publication bias, selective
reporting within studies).
16 Describe methods of additional analyses (e.g., sensitivity or
subgroup analyses, meta-regression), if done, indicating
which were pre-specified.

55-56

17 Give numbers of studies screened, assessed for eligibility,
and included in the review, with reasons for exclusions at
each stage, ideally with a flow diagram.
18 For each study, present characteristics for which data were
extracted (e.g., study size, PICOS, follow-up period) and
provide the citations.
19 Present data on risk of bias of each study and, if available,
any outcome level assessment (see item 12).

57

63-76

Synthesis of
results

20 For all outcomes considered (benefits or harms), present,
for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence
intervals, ideally with a forest plot.
21 Present results of each meta-analysis done, including
confidence intervals and measures of consistency.

Risk of bias
across studies

22 Present results of any assessment of risk of bias across
studies (see Item 15).

60-62

Additional
analysis

23 Give results of additional analyses, if done (e.g., sensitivity
or subgroup analyses, meta-regression [see Item 16]).

63-76

24 Summarize the main findings including the strength of
evidence for each main outcome; consider their relevance to
key groups (e.g., healthcare providers, users, and policy
makers).

77-84

Risk of bias
across studies
Additional
analyses
RESULTS
Study selection
Study
characteristics
Risk of bias
within studies
Results of
individual
studies

DISCUSSION
Summary of
evidence

36-39
45-46
55-56

58-60
60-62

63-76
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Appendix B: Systematic Review Search Strategies
DATABASE
OVID
Medline

1
2
3
4
5

6
7

8

9
10

11

SEARCH TERMS
exp Cataract Extraction/ or exp Cataract/
(Phacoemulsif* or Phakoemulsif* or Phaco-emul* or Phakoemul* or Cataract extrac* or Cataract remov* or Cataract
surg* or Cataract operat*).mp
1 or 2
neuroleptanalgesia/ or anesthesia/ or anesthesia, local/ or
nerve block/ or anesthesia, intravenous/ or cryoanesthesia/
or analgesia/ or exp Anesthetics/ or exp Perioperative care/
(((block or anesthe* or anaesthe* or infiltrat* or inject*) adj3
(orbicularis or subtenon or peribulbar or retrobulbar or
topical or intracameral or intracameral)) or Xylocaine or
Neurolept* or Benzodiazep* or Lidocaine or Intracameral or
Intracameral* Procaine or Proparacaine or Oxybuprocaine
or Tetracaine or Bupivacaine or Etidocaine or Lidocaine or
Prilocaine or Ropicacaine or Cryoanalg* or cryoanalg* or
Cryoanesthes* or Cryoanaesthes* or midazolam or
Fentanyl or Propofol or Perifentanyl or Gravol or
dimenhydrinate or ondansetron or lorazepam or Ativan or
valium or diphenhydramine or benadryl).mp.
4 or 5
pain/ or eye pain/ or pain, postoperative/ or Postoperative/
or Postoperative Period/ or Perioperative Care/ or
Perioperative Period/ or Intraoperative Care/ or
Intraoperative Period/ or hyphema/
((pain or ache or aching or discomfort or instil* or drop or
dilat* or manipulation or manipulat* or freez* or pressure or
headache) adj3 (postop* or post-op* or periop* or peri-op*
or Intraop* or intra-op*)).mp.
7 or 8
Intraoperative Complications/ or Postoperative
Complications/ or Endophthalmitis/ or Keratitis/ or Lens
Subluxation/ or Retinal Detachment/ or Vision Disorders/ or
Eye Hemorrhage/ or Vitreous Hemorrhage/ or Retinal
Hemorrhage/
(complication* or broken capsul* or posterior capsule
ruptur* or endophthalmitis or keratitis or intraocular lens
dislocation* or lens subluxat * or low ocular pressure or
ocular hypotens* or high ocular pressure or ocular
hypertens* or anesthetic allergy or ocular toxicit* or allergic
reaction* or vitreous hemorrhag* or retinal detachment* or
choroidal hemorrhag* or suprachoroidal hemorrhag* or
ocular hemorrha* or eye hemorrhag* or retinal hemorrhag*
or systemic hypertension or vision loss* or vision
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disorder*).mp.
10 or 11
3 and 6 and 9
3 and 6 and 12
13 or 14
limit 15 to (human and english language and yr="1995 Current")
RESULTS 1208
Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
1946 to Present
12
13
14
15
16

OVID
Embase

1
2
3
4
5

6
7

8

9
10

exp Cataract Extraction/ or exp Cataract/
(Phacoemulsif* or Phakoemulsif* or Phaco-emul* or Phakoemul* or Cataract extrac* or Cataract remov* or Cataract
surg* or Cataract operat*).mp.
1 or 2
neuroleptanalgesia/ or anesthesia/ or anesthesia, local/ or
nerve block/ or anesthesia, intravenous/ or cryoanesthesia/
or analgesia/ or exp Anesthetics/ or exp Perioperative care/
(((block or anesthe* or anaesthe* or infiltrat* or inject*) adj3
(orbicularis or subtenon or peribulbar or retrobulbar or
topical or intracameral or intracameral)) or Xylocaine or
Neurolept* or Benzodiazep* or Lidocaine or Intracameral or
Intracameral* Procaine or Proparacaine or Oxybuprocaine
or Tetracaine or Bupivacaine or Etidocaine or Lidocaine or
Prilocaine or Ropicacaine or Cryoanalg* or cryoanalg* or
Cryoanesthes* or Cryoanaesthes* or midazolam or
Fentanyl or Propofol or Perifentanyl or Gravol or
dimenhydrinate or ondansetron or lorazepam or Ativan or
valium or diphenhydramine or benadryl).mp.
4 or 5
pain/ or eye pain/ or pain, postoperative/ or Postoperative/
or Postoperative Period/ or Perioperative Care/ or
Perioperative Period/ or Intraoperative Care/ or
Intraoperative Period/ or hyphema/
((pain or ache or aching or discomfort or instil* or drop or
dilat* or manipulation or manipulat* or freez* or pressure or
headache) adj3 (postop* or post-op* or periop* or peri-op*
or Intraop* or intra-op*)).mp.
7 or 8
Intraoperative Complications/ or Postoperative
Complications/ or Endophthalmitis/ or Keratitis/ or Lens
Subluxation/ or Retinal Detachment/ or Vision Disorders/ or
Eye Hemorrhage/ or Vitreous Hemorrhage/ or Retinal
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Hemorrhage/
(complication* or broken capsul* or posterior capsule
ruptur* or endophthalmitis or keratitis or intraocular lens
dislocation* or lens subluxat* or low ocular pressure or
ocular hypotens* or high ocular pressure or ocular
hypertens* or anesthetic allergy or ocular toxicit* or allergic
reaction* or vitreous hemorrhag* or retinal detachment* or
choroidal hemorrhag* or suprachoroidal hemorrhag* or
ocular hemorrha* or eye hemorrhag* or retinal hemorrhag*
or systemic hypertension or vision loss* or vision
disorder*).mp.
12
10 or 11
13
3 and 6 and 9
14
3 and 6 and 12
15
13 or 14
16
limit 15 to (human and english language and yr="1995 Current")
RESULTS 1670
Embase Classic+Embase <1947 to 2017 September 8>
11

CINAHL

1
2
3
4

5

6
7

(MH "Cataract Extraction+") or (MH "Cataract")
Phacoemulsif* or Phakoemulsif* or Phaco-emul* or Phakoemul* or Cataract extrac* or Cataract remov* or Cataract
surg* or Cataract operat*
S1 OR S2
(MH "Anesthesia") OR (MH "Anesthesia, Local") OR (MH
"Nerve Block") OR (MH "Anesthesia, Intravenous") OR (MH
"Analgesia") OR (MH "Anesthetics") OR (MH "Anesthetics,
Local") OR (MH "Anesthetics, Intravenous") OR (MH
"Analgesia") OR (MH "Anesthesia and Analgesia")
((block or anesthe* or anaesthe* or infiltrat* or inject*) N3
(orbicularis or subtenon or peribulbar or retrobulbar or
topical or intracameral or intracameral)) or Xylocaine or
Neurolept* or Benzodiazep* or Lidocaine or Intracameral or
Intracameral* Procaine or Proparacaine or Oxybuprocaine
or Tetracaine or Bupivacaine or Etidocaine or Lidocaine or
Prilocaine or Ropicacaine or Cryoanalg* or cryoanalg* or
Cryoanesthes* or Cryoanaesthes* or midazolam or
Fentanyl or Propofol or Perifentanyl or Gravol or
dimenhydrinate or ondansetron or lorazepam or Ativan or
valium or diphenhydramine or benadryl
S4 OR S5
(MH "Pain") OR (MH "Postoperative Pain") OR (MH "Eye
Pain") OR (MH "Postoperative Period") OR (MH
"Postoperative Care") OR (MH "Intraoperative Care") OR
(MH "Intraoperative Period") OR (MH "Perioperative Care")
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OR (MH "Eye Hemorrhage")
(pain or ache or aching or discomfort or instil* or drop or
dilat* or manipulation or manipulat* or freez* or pressure or
headache) N3 (postop* or post-op* or periop* or peri-op* or
Intraop* or intra-op*)
9
S7 OR S8
10
(MH "Postoperative Complications") OR (MH
"Intraoperative Complications") OR (MH "Endophthalmitis")
OR (MH "Keratitis") OR (MH "Keratitis, Fungal") OR (MH
"Keratitis, Bacterial") OR (MH "Corneal Ulcer") OR (MH
"Retinal Detachment") OR (MH "Eye Hemorrhage") OR
(MH "Vision Disorders")
11
complication* or broken capsul* or posterior capsule ruptur*
or endophthalmitis or keratitis or intraocular lens
dislocation* or lens subluxat* or low ocular pressure or
ocular hypotens* or high ocular pressure or ocular
hypertens* or anesthetic allergy or ocular toxicit* or allergic
reaction* or vitreous hemorrhag* or retinal detachment* or
choroidal hemorrhag* or suprachoroidal hemorrhag* or
ocular hemorrha* or eye hemorrhag* or retinal hemorrhag*
or systemic hypertension or vision loss* or vision disorder*
12
S10 OR S11
13
S3 AND S6 AND S9
14
S3 AND S6 AND S12
15
S13 OR S14
16
Limit - Published Date: 19950101-20160931; English
Language; Human
RESULTS 21
Interface - EBSCOhost Research Databases
Search Screen - Advanced Search
Database - CINAHL
8

WEB OF
SCIENCE

1

2

Phacoemulsif* or Phakoemulsif* or Phaco-emul* or Phakoemul* or Cataract extrac* or Cataract remov* or Cataract
surg* or Cataract operat*
((block or anesthe* or anaesthe* or infiltrat* or inject*)
NEAR/3 (orbicularis or subtenon or peribulbar or
retrobulbar or topical or intracameral or intracameral)) or
Xylocaine or Neurolept* or Benzodiazep* or Lidocaine or
Intracameral or Intracameral* Procaine or Proparacaine or
Oxybuprocaine or Tetracaine or Bupivacaine or Etidocaine
or Lidocaine or Prilocaine or Ropicacaine or Cryoanalg* or
cryoanalg* or Cryoanesthes* or Cryoanaesthes* or
midazolam or Fentanyl or Propofol or Perifentanyl or Gravol
or dimenhydrinate or ondansetron or lorazepam or Ativan
or valium or diphenhydramine or benadryl
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3

pain or ache or aching or discomfort or instil* or drop or
dilat* or manipulation or manipulat* or freez* or pressure or
headache or eye pain
4
complication* or broken capsul* or posterior capsule ruptur*
or endophthalmitis or keratitis or intraocular lens
dislocation* or lens subluxat* or low ocular pressure or
ocular hypotens* or high ocular pressure or ocular
hypertens* or anesthetic allergy or ocular toxicit* or allergic
reaction* or vitreous hemorrhag* or retinal detachment* or
choroidal hemorrhag* or suprachoroidal hemorrhag* or
ocular hemorrha* or eye hemorrhag* or retinal hemorrhag*
or systemic hypertension or vision loss* or vision disorder*
5
#3 AND #2 AND #1
6
#4 AND #2 AND #1
7
#6 OR #5
8
(#6 OR #5) AND LANGUAGE: (English)
RESULTS 777
Timespan=1995-2016
Indexes=Science Citation Index Expanded (SCIEXPANDED) --1945-present, Social Sciences Citation
Index (SSCI) --1900-present, Conference Proceedings
Citation Index- Science (CPCI-S) --1990-present,
Conference Proceedings Citation Index- Social Science &
Humanities (CPCI-SSH) 1990-present, Emerging Sources
Citation Index (ESCI) --2015-present
BIOSIS
Previews

1
2

3

4

Phacoemulsif* or Phakoemulsif* or Phaco-emul* or Phakoemul* or Cataract extrac* or Cataract remov* or Cataract
surg* or Cataract operat*
((block or anesthe* or anaesthe* or infiltrat* or inject*)
NEAR/3 (orbicularis or subtenon or peribulbar or
retrobulbar or topical or intracameral or intracameral)) or
Xylocaine or Neurolept* or Benzodiazep* or Lidocaine or
Intracameral or Intracameral* Procaine or Proparacaine or
Oxybuprocaine or Tetracaine or Bupivacaine or Etidocaine
or Lidocaine or Prilocaine or Ropicacaine or Cryoanalg* or
cryoanalg* or Cryoanesthes* or Cryoanaesthes* or
midazolam or Fentanyl or Propofol or Perifentanyl or Gravol
or dimenhydrinate or ondansetron or lorazepam or Ativan
or valium or diphenhydramine or benadryl
pain or ache or aching or discomfort or instil* or drop or
dilat* or manipulation or manipulat* or freez* or pressure or
headache or eye pain
complication* or broken capsul* or posterior capsule ruptur*
or endophthalmitis or keratitis or intraocular lens
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dislocation* or lens subluxat* or low ocular pressure or
ocular hypotens* or high ocular pressure or ocular
hypertens* or anesthetic allergy or ocular toxicit* or allergic
reaction* or vitreous hemorrhag* or retinal detachment* or
choroidal hemorrhag* or suprachoroidal hemorrhag* or
ocular hemorrha* or eye hemorrhag* or retinal hemorrhag*
or systemic hypertension or vision loss* or vision disorder*
5
#3 AND #2 AND #1
6
#4 AND #2 AND #1
7
#6 OR #5
8
(#6 OR #5) Refined by: LANGUAGES: (ENGLISH)
Previews Timespan=1995-2016
RESULTS 284
Indexes=BIOSIS Previews
Cochrane

1
2
3
4
5
6
7
8
9
10
11
12
13
14

15
16
17

[Cataract Extraction] explode all trees
[Cataract] explode all trees
(Phacoemulsif* or Phakoemulsif* or Phaco-emul* or Phakoemul* or Cataract extrac* or Cataract remov* or Cataract
surg* or Cataract operat*)
#1 or #2 or #3
[Anesthesia] this term only
[Neuroleptanalgesia] this term only
[Anesthesia, Local] this term only
[Nerve Block] this term only
[Anesthesia, Intravenous] this term only
[Cryoanesthesia] this term only
[Analgesia] this term only
[Anesthetics] explode all trees
[Perioperative Care] explode all trees
(((block or anesthe* or anaesthe* or infiltrat* or inject*) adj3
(orbicularis or subtenon or peribulbar or retrobulbar or
topical or intracameral or intracameral)) or Xylocaine or
Neurolept* or Benzodiazep* or Lidocaine or Intracameral or
Intracameral* Procaine or Proparacaine or Oxybuprocaine
or Tetracaine or Bupivacaine or Etidocaine or Lidocaine or
Prilocaine or Ropicacaine or Cryoanalg* or cryoanalg* or
Cryoanesthes* or Cryoanaesthes* or midazolam or
Fentanyl or Propofol or Perifentanyl or Gravol or
dimenhydrinate or ondansetron or lorazepam or Ativan or
valium or diphenhydramine or benadryl)
#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or
#14
[Pain] this term only
[Pain, Postoperative] this term only
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18
19
20
21
22
23
24
25

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45
46
47
48

[Eye Pain] this term only
[Facial Pain] this term only
[Headache] this term only
[Pain Management] this term only
[Pain Measurement] this term only
[Eye Injuries] this term only
[Dizziness] this term only
((pain or ache or aching or discomfort or instil* or drop or
dilat* or manipulation or manipulat* or freez* or pressure or
headache) adj3 (postop* or post-op* or periop* or peri-op*
or Intraop* or intra-op*))
#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or
#24 or #25
[Intraoperative Complications] this term only
[Postoperative Complications] this term only
[Endophthalmitis] this term only
[Eye Infections] this term only
[Corneal Ulcer] this term only
[Eye Infections, Bacterial] this term only
[Eye Infections, Fungal] this term only
[Keratitis] this term only
[Retinal Detachment] this term only
[Retinal Hemorrhage] this term only
[Eye Hemorrhage] this term only
[Choroid Hemorrhage] this term only
[Vitreous Hemorrhage] this term only
[Vision Disorders] explode all trees
[Ocular Hypertension] this term only
[Ocular Hypotension] this term only
[Eye Diseases] explode all trees
(complication* or broken capsul* or posterior capsule
ruptur* or endophthalmitis or keratitis or intraocular lens
dislocation* or lens subluxat* or low ocular pressure or
ocular hypotens* or high ocular pressure or ocular
hypertens* or anesthetic allergy or ocular toxicit* or allergic
reaction* or vitreous hemorrhag* or retinal detachment* or
choroidal hemorrhag* or suprachoroidal hemorrhag* or
ocular hemorrha* or eye hemorrhag* or retinal hemorrhag*
or systemic hypertension or vision loss* or vision disorder*)
#27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or
#35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or
#43 or #44
#4 and #15 and #26
#4 and #15 and #45
#46 or #47 Publication Year from 1995 to 2016
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RESULTS 540
Cochrane Reviews, Other Reviews, Trials, Methods
Studies, Technology Assessments, Economic Evaluations,
Cochrane Groups
TYPE
Grey
Literature
(General)
Clinical
Trials

Conference
Proceedings
Reports

RESULT
4
n/a
n/a
3
33
n/a
n/a
n/a

n/a
n/a
n/a
Theses and n/a
Dissertations n/a
n/a

Ophthalmology Specific

n/a
n/a
n/a
1
n/a

DATABASE/WEBSITE
Grey Matters (CADTH - Canadian Agency for Drugs and
Technologies in Health)
Open Grey
Grey Literature Report
ClinicalTrials.gov
International Clinical Trials Registry
UK Clinical Trials Gateway
UK Clinical Research Network Study Portfolio
World Cat
Centers for Disease Control and Prevention
Health Canada
World Health Organization
Electronic Thesis Online Service (EThoS)
NDLTD http://serach.ndltd.org/
Theses Canada Portal
http://amicus.collectionscanada.gc.ca/thesescanadabin/Main/Ba sicSearch?coll=18&l=0&v=1
Western Theses and Dissertations (UWO Catalogue)
Association for Research in Vision and Ophthalmology
(ARVO) Conference Abstracts
American Academy of Ophthalmology (AAO)
Canadian Society of Ophthalmology (COS)
European Society of Ophthalmology (SOE)
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Appendix C: Imputation Calculations
Aydin et al. (2002)
To impute the standard deviation of Intravenous Fentanyl Group and control group
using the mean and p values:
• Mean for intervention = 1.16, mean for control= 0.52
• The P Value for the comparison is 0.02, obtained using a two sample t-test.
• Degrees of freedom = n1-1 + n2-1 = (34-1) + (34-1) = 66
• t is 2.38418574. Obtained from a table of the t distribution with 66 degrees of
freedom or an excel spreadsheet (enter =tinv(0.02,66)
NOTE: The calculated standard deviation is the average of the standard deviations of
the intervention and comparator arms, and should be entered into the analysis software
for the intervention and comprator.
𝑺𝑬 = 𝑴𝑫 𝒕 = 𝟏. 𝟏𝟔 − 𝟎. 𝟓𝟐 𝟐. 𝟑𝟖𝟒𝟏𝟖𝟓𝟕𝟒 = 𝟎. 𝟐𝟔𝟖𝟒𝟑𝟓𝟒𝟔
𝑺𝑫 =

𝑺𝑬
𝟏
𝟏
+
𝑵𝒆 𝑵𝒄

=

𝟎. 𝟐𝟔𝟖𝟒𝟑𝟓𝟒𝟔
𝟎. 𝟎𝟓𝟖𝟖

= 𝟎. 𝟏𝟎𝟔𝟕𝟖𝟕𝟕𝟔

Leidinger et al. (2005)
The following data and calculations were done based on Figure 1(a) in the article, which
plots the distribution of the visual analogue scores 3 minutes after retrobulbar block –
the x-axis is the visual analogue score and the y-axis is the number of patients.
Saline
• Numbers in the data set = 2, 2, 2, 3, 3, 3, 3,
3, 3, 3, 3, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6,
6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8,
8, 10
• Mean = 𝑋 𝑛 = 5.53333
• Standard Deviation =
(𝑋 − 𝑀)T 𝑛 =
2.06265

Score

IV Remifentanil
• Numbers in the data set = 1, 1, 1, 1, 2, 2, 2,
2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2,
3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 5,
5, 6
• Mean = 𝑋 𝑛 = 2.57778
• Standard Deviation =
(𝑋 − 𝑀)T 𝑛 = 1.05505

0
1
2
3
4
5
6
7
8
9
10

Saline
# of patients
0
0
3
8
3
8
5
9
8
0
1

Remifentanil
# of patients
0
4
21
14
3
2
1
0
0
0
0
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Akgul et al. (2007)
This study has two intervention groups and one comparator group. We have decided to
combine the two intervention groups into one so that a pair-wise comparison is possible
in the meta-analysis. 15 minutes after the surgery had begun, pain score ratings were
taken. Group: Fentanyl – VPS 0.2, p=0.014, Remifentanil – VPS 0.3, p=0.021, Control –
VPS 0.7
Impute SD of IV Fentanyl to Control
• The P Value for the comparison is 0.014 @ 15 minutes, obtained using a two
sample t-test. The t value that corresponds with a P value of 0.014
• Degrees of freedom = n1-1 + n2-1 = (40-1) + (40-1) = 78
o T Procedure for two independent populations = conservative
approximation https://www.thoughtco.com/how-to-find-degrees-offreedom-3126409
• t = 2.5139004. Obtained from a table of the t distribution with 78 degrees of
freedom or an excel spreadsheet (in a cell enter =tinv(0.014,78)
𝑺𝑬 = 𝑴𝑫 𝒕 = 𝟎. 𝟕 − 𝟎. 𝟐 𝟐. 𝟓𝟏𝟑𝟗𝟎𝟎𝟒 = 𝟎. 𝟏𝟗𝟖𝟖𝟗𝟒𝟏𝟐
𝑺𝑫 =

𝑺𝑬
𝟏
𝟏
+
𝑵𝒆 𝑵𝒄

=

𝟎. 𝟏𝟗𝟖𝟖𝟗𝟒𝟏𝟐
𝟎. 𝟎𝟓

=

𝟎. 𝟏𝟗𝟖𝟖𝟗𝟒𝟏𝟐
= 𝟎. 𝟖𝟖𝟗𝟒𝟖𝟏𝟓𝟓
𝟎. 𝟐𝟐𝟑𝟔𝟎𝟔𝟖

Impute SD of IV Remifentanil to Control
• The P Value for the comparison is 0.021 @ 15 minutes, obtained using a two
sample t-test.The t value that corresponds with a P value of 0.021
• Degrees of freedom = n1-1 + n2-1 = (40-1) + (40-1) = 78
• t is 2.5139004. Obtained from a table of the t distribution with 78 degrees of
freedom or Microsoft excel (=tinv(0.014,78)
𝑺𝑬 = 𝑴𝑫 𝒕 = 𝟎. 𝟕 − 𝟎. 𝟑 𝟐. 𝟓𝟏𝟑𝟗𝟎𝟎𝟒 = 𝟎. 𝟏𝟓𝟗𝟏𝟏𝟓𝟐𝟗
𝑺𝑫 =

𝑺𝑬
𝟏
𝟏
+
𝑵𝒆 𝑵𝒄

=

𝟎. 𝟏𝟓𝟗𝟏𝟏𝟓𝟐𝟗
𝟎. 𝟎𝟓

=

𝟎. 𝟏𝟓𝟗𝟏𝟏𝟓𝟐𝟗
= 𝟎. 𝟕𝟏𝟏𝟓𝟖𝟓
𝟎. 𝟐𝟐𝟑𝟔𝟎𝟔𝟖

The standard deviations were combined according to the Cochrane Handbook:
𝑺𝑫 =

𝑵𝟏𝑵𝟐
𝑴𝟏𝟐 + 𝑴𝟐𝟐 − 𝟐𝑴𝟏𝑴𝟐
𝑵𝟏 + 𝑵𝟐
𝑵𝟏 + 𝑵𝟐 − 𝟏

𝑵𝟏 − 𝟏 𝑺𝑫𝟏𝟐 + 𝑵𝟐 − 𝟏 𝑺𝑫𝟐𝟐 +

𝟑𝟗 𝟎. 𝟖𝟖𝟗𝟒𝟖𝟏𝟐 + 𝟑𝟗 𝟎. 𝟕𝟏𝟏𝟓𝟖𝟓𝟐 +
𝟕𝟗
𝟑𝟎. 𝟖𝟓𝟓𝟖𝟖𝟏𝟓 + 𝟏𝟗. 𝟕𝟒𝟕𝟕𝟕𝟓𝟑 + 𝟎. 𝟐
𝟕𝟗
=0.80192535

𝟏𝟔𝟎𝟎
𝟎. 𝟐𝟐 + 𝟎. 𝟑𝟐 − 𝟐𝒙𝟎. 𝟐𝒙𝟎. 𝟑
𝟖𝟎
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Santiago et al. (2014)
This research study reports the mean and standard deviation of the intravenous and
placebo group at 9 stages throughout the procedure. To get an overall effect estimate,
we averaged the mean’s and standard deviation’s. The following chart depicts the
process of averaging the standard deviation.
Formula: Average SD =
Stage of
Cataract
Extraction
1
2
3
4
5
6
7
8
9
SUM
/9
Square
Root

Mean
0.2
0.2
0.2
0.2
0.9
3.9
3.1
3.6
1.8
14.1
1.57

WXYZ [WXTZ [⋯[ WX]Z
]

Placebo
Standard
Deviation
0.7
0.7
0.7
0.5
1.3
3.2
2.7
2.4
1.8

Variance
2
(SD )
0.49
0.49
0.49
0.25
1.69
10.24
7.29
5.76
3.24
29.94
3.326666667
1.82

Mean
0.3
0.3
0.3
0.3
0.5
1.4
1.4
1.7
1.1
7.3
0.81

IV Clonidine
Standard
Deviation
0.9
0.9
0.9
0.9
1.1
1.6
2
2
1.7

Variance
2
(SD )
0.81
0.81
0.81
0.81
1.21
2.56
4
4
2.89
17.9
1.988888889
1.41

Chen et al. (2015)
There were 6 cases of pain in the study:
• 3 patients in the IV midazolam group reported a level 1 (mild) on NRS-11 scale
• 4 patients in the oral diazepam group reported a level 1 (mild) on NRS-11 scale
• Since level 1 on the NRS-11 scale is a rating of 1-3, we will use a rating of 2 to
calculate the mean and standard deviation.
Oral Diazepam
• Numbers in the data set = 2, 2, 2, and 70 ratings of 0
• Mean = 𝑋 𝑛 = 0.082
• Standard Deviation =
(𝑋 − 𝑀)T 𝑛 = 0.3998
IV Midazolam
• Numbers in the data set = 2, 2, 2, and 80 ratings of 0
• Mean = 𝑋 𝑛 = 0.072
• Standard Deviation =
(𝑋 − 𝑀)T 𝑛 = 0.3756
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Ghodki et al. (2015)
To impute the standard deviation of Intravenous Dexmedetomidine Group and control
group using the mean and p values:
• Mean for intervention = 3, mean for control= 3
• The P Value for the comparison is 0.182, obtained using a two sample t-test.
• Degrees of freedom = n1-1 + n2-1 = (30-1) + (30-1) = 58
• t is 1.35081913. This can be obtained from a table of the t distribution with 66
degrees of freedom or from a computer (entering =tinv(0.182,58) into any cell in
a Microsoft Excel spreadsheet.
𝑺𝑬 = 𝑴𝑫 𝒕 = 𝟑 − 𝟑 𝟏. 𝟑𝟓𝟎𝟖𝟏𝟗𝟏𝟑 = 𝐍𝐨𝐭 𝐄𝐬𝐭𝐢𝐦𝐢𝐚𝐛𝐥𝐞
Added in a correction factor of 0.1
𝑺𝑬 = 𝑴𝑫 𝒕 = 𝟎. 𝟏 𝟏. 𝟑𝟓𝟎𝟖𝟏𝟗𝟏𝟑 = 𝟎. 𝟎𝟕𝟒𝟎𝟐𝟗𝟏𝟔
𝑺𝑫 =

𝑺𝑬
𝟏
𝟏
+
𝑵𝒆 𝑵𝒄

=

𝟎. 𝟎𝟕𝟒𝟎𝟐𝟗𝟏𝟔
𝟎. 𝟎𝟔𝟔𝟕

= 𝟎. 𝟐𝟖𝟔𝟕

Habib et al. (2004)
Lastly, Habib et al. (2004) was the most challenging study to impute the standard
deviation. P values, confidence intervals, and numbers in the dataset were absent from
the article and not available through the corresponding author. An experienced
researcher suggested the following method: Calculate the standard deviation as a
percentage of mean, and use the average of that for all the other studies. Then, apply
that no to the mean of the missing study.
Study ID
116
Aydin et al. (2002)
117
Inan et al. (2003)
118
Laube et al. (2003)
120
Leidinger et al. (2005)
121
Akgul et al. (2007)
122
Erdurmus et al. (2008)
123

Santiago et al. (2014)
56
Chen et al. (2015)
124
Ghodki et al. (2015)
Average
Habib et al. (2004)

131

IV Sedation Group
Mean SD
% SD/mean
0.52
1.11
2.134615385
0.08
0.27
3.375
0.18
0.44
2.444444444
2.58
1.06
0.410852713
0.25
0.8
3.2
1.23
1.72
1.398373984

Non-IV Sedation Group
Mean SD
% SD/mean
1.16 1.11 0.956896552
1.06 0.25 0.235849057
0.13 0.61 4.692307692
5.53 2.06 0.372513562
0.7
0.8 1.142857143
3.64 1.43 0.392857143

0.81
0.072
3

1.740740741
5.277777778
0.096666667
2.230941301

1.57
0.082
3

0.29 * 2.230941301 =
0.646

0.38

0.29

1.41
0.38
0.29

1.82
0.4
0.29

1.159235669
4.87804878
0.096666667
1.547470252

0.38 * 1.547470252
= 0.588
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Appendix D: Stata Code
Outcome
Pain
Perception

Analysis
Metaanalysis
SMD

Stata Code
metan n1 m1 sd1 n2 m2 sd2, random xlabel(-4,-3,-2,1,0,1,1,2,3,4) title("Effect of Intravenous Sedation on Pain
Perception") xtitle("Standardized mean difference")
textsize(150) favours(IV sedation reduces pain # Non-IV
methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) graphregion(color(white))

Sensitivity
analysis

drop in 2
drop in 4

Sensitivity
Analysis

Metaanalysis
WMD

Subgroup
Analysis
(Intravenous
Sedative)
Subgroup
Analysis
(Non-IV
Methods)

metan n1 m1 sd1 n2 m2 sd2, random xlabel(-4,-3,-2,1,0,1,1,2,3,4) title("Sensitivity Analysis for Pain
Perception") xtitle("Standardized mean difference")
textsize(150) favours(IV sedation reduces pain # Non-IV
methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) graphregion(color(white))
drop in 1
drop in 3
drop in 4
drop in 7
metan n1 m1 sd1 n2 m2 sd2, random xlabel(-4,-3,-2,1,0,1,1,2,3,4) title("Sensitivity Analysis for Pain
Perception") xtitle("Standardized mean difference")
textsize(150) favours(IV sedation reduces pain # Non-IV
methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) graphregion(color(white))
**converted scale**
metan n1 m1 sd1 n2 m2 sd2, nostandard random
title("Effect of Intravenous Sedation on Pain Perception")
textsize(150) favours(IV sedation reduces pain # Non-IV
methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) graphregion(color(white))
metan n1 m1 sd1 n2 m2 sd2, fixed xlabel(-4,-3,-2,1,0,1,1,2,3,4) title("Sub-group Analysis by Intravenous
Sedative") xtitle("Standardized mean difference")
textsize(125) favours(IV sedation reduces pain # Non-IV
methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) by(intervention) graphregion(color(white))
metan n1 m1 sd1 n2 m2 sd2, fixed xlabel(-4,-3,-2,1,0,1,1,2,3,4) title("Sub-group Analysis by Non-Intravenous
Methods") xtitle("Standardized mean difference")
textsize(125) favours(IV sedation reduces pain # Non-IV
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Metaregression

methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) by(comparator) graphregion(color(white))
metan n1 m1 sd1 n2 m2 sd2, random xlabel(-4,-3,-2,1,0,1,1,2,3,4) title("Effect of Intravenous Sedation on Pain
Perception") xtitle("Standardized mean difference")
textsize(150) favours(IV sedation reduces pain # Non-IV
methods reduce pain) lcols(author year) boxsca(0) xsize(5)
ysize(3) graphregion(color(white))
metareg _ES reglocation, wsse( _seES)
metareg _ES regyear, wsse( _seES)
metareg _ES regage, wsse( _seES)

metareg _ES regsex, wsse( _seES)
metafunnel _ES _seES, xlab(-4 -3 -2 -1 0 1 2 3) ylab(-.2 .1 0 .1 .2 .3 .4) xtitle(Standardized mean difference)
ytitle(Standard error of SMD) graphregion(color(white))
Metametan n1 comp1 n2 comp2, rr title("Effect of Intravenous
analysis RR
Sedation on Adverse Events") xtitle("Risk Ratio")
textsize(150) favours(IV sedation increase complications #
Non-IV methods increase complications) lcols(author year)
boxsca(0) xsize(6) ysize(3) graphregion(color(white))
Metametan n1 comp1 n2 comp2, rr nointeger title("Effect of
analysis RR
Intravenous Sedation on Adverse Events") xtitle("Risk
with
Ratio") textsize(150) favours(IV sedation increase
correction
complications # Non-IV methods increase complications)
factor
lcols(author year) boxsca(0) xsize(6) ysize(3)
graphregion(color(white))
Funnel plot
metafunnel _ES _selogES, xlab(0.5 1 1.5) ylab(0 0.05 .1 )
complications xtitle(Risk Ratio) ytitle(Standard error of RR)
graphregion(color(white))
Funnel Plot

Adverse
Events
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